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Abstract
Patterns of DNA methylation are established and maintained by DNA methyltransferases (Dnmts), which
have traditionally been subdivided into the ‘de novo’ methyltransferases, Dnmt3a and Dnmt3b, and the
‘maintenance’ methyltransferase, Dnmt1. Dnmt1 maintains DNA methylation patterns and genomic stability
in several in vitro cell systems, but its function in tissue-specific development, homeostasis, and disease in vivo
is only beginning to be investigated.
Recently, the Kaestner lab demonstrated that loss of Dnmt1 in the adult intestinal epithelium causes a two-
fold expansion of the proliferative crypt zone, indicating that Dnmt1 and DNA methylation regulate
proliferative processes in the intestine. I hypothesized that loss of Dnmt1 may impart similar effects during
intestinal development and tumorigenesis, and employed distinct Cre-loxP mouse models to ablate Dnmt1 in
progenitor cells during intestinal development and in the mature intestinal epithelium of cancer-prone
ApcMin/+ mice.
In the first part of my thesis, I show that loss of Dnmt1 in intervillus progenitor cells in the developing
intestine causes global hypomethylation, DNA damage, premature differentiation, and apoptosis. I confirm
this novel role for Dnmt1 during crypt development using the in vitro organoid culture system, and illustrate a
differential requirement for Dnmt1 in immature versus mature organoids. These results demonstrate an
essential role for Dnmt1 in maintaining genomic stability during intestinal development and the
establishment of intestinal crypts.
DNA methylation is thought to drive CRC progression by the repression of tumor suppressor genes via
promoter methylation. In the second part of my thesis, I utilize inducible intestinal epithelial-specific gene
ablation to determine the requirement of Dnmt1 in intestinal tumorigenesis. Surprisingly, I find that loss of
Dnmt1 in cancer-prone ApcMin/+ mice results in accelerated, not decreased, intestinal tumor development.
Dnmt1 deletion precipitates an acute response in mature intestinal epithelium characterized by
hypomethylation of repetitive elements, genomic instability, and apoptosis, which is followed by
remethylation with time. This recovery is entirely dependent on the activity of the de novo methyltransferase
Dnmt3b. In light of these data, the current dogma regarding the role of DNA methylation in colon cancer
needs to be revisited.
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ABSTRACT 
 
 
DNMT1 IN INTESTINAL DEVELOPMENT AND CANCER 
 
 
Ellen N. Elliott 
 
 
Klaus H. Kaestner 
 
 
Patterns of DNA methylation are established and maintained by DNA methyltransferases 
(Dnmts), which have traditionally been subdivided into the ‘de novo’ methyltransferases, Dnmt3a 
and Dnmt3b, and the ‘maintenance’ methyltransferase, Dnmt1. Dnmt1 maintains DNA 
methylation patterns and genomic stability in several in vitro cell systems, but its function in 
tissue-specific development, homeostasis, and disease in vivo is only beginning to be 
investigated.  
Recently, the Kaestner lab demonstrated that loss of Dnmt1 in the adult intestinal 
epithelium causes a two-fold expansion of the proliferative crypt zone, indicating that Dnmt1 and 
DNA methylation regulate proliferative processes in the intestine. I hypothesized that loss of 
Dnmt1 may impart similar effects during intestinal development and tumorigenesis, and employed 
distinct Cre-loxP mouse models to ablate Dnmt1 in progenitor cells during intestinal development 
and in the mature intestinal epithelium of cancer-prone ApcMin/+ mice.  
In the first part of my thesis, I show that loss of Dnmt1 in intervillus progenitor cells in the 
developing intestine causes global hypomethylation, DNA damage, premature differentiation, and 
apoptosis. I confirm this novel role for Dnmt1 during crypt development using the in vitro organoid 
culture system,	   and illustrate a differential requirement for Dnmt1 in immature versus mature 
organoids. These results demonstrate an essential role for Dnmt1 in maintaining genomic stability 
during intestinal development and the establishment of intestinal crypts.  
DNA methylation is thought to drive CRC progression by the repression of tumor 
suppressor genes via promoter methylation. In the second part of my thesis, I utilize inducible 
intestinal epithelial-specific gene ablation to determine the requirement of Dnmt1 in intestinal 
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tumorigenesis. Surprisingly, I find that loss of Dnmt1 in cancer-prone ApcMin/+ mice results in 
accelerated, not decreased, intestinal tumor development. Dnmt1 deletion precipitates an acute 
response in mature intestinal epithelium characterized by hypomethylation of repetitive elements, 
genomic instability, and apoptosis, which is followed by remethylation with time. This recovery is 
entirely dependent on the activity of the de novo methyltransferase Dnmt3b. In light of these data, 
the current dogma regarding the role of DNA methylation in colon cancer needs to be revisited.  
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Chapter One 
 
Introduction 
 
Epigenetic regulation of the intestinal epithelium 
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Introduction 
 
Waddington coined the term “epigenetics” in 1942 to describe the burgeoning field of 
developmental biology, and the mechanisms underlying development from the undifferentiated 
embryo to the mature adult organism (Waddington 1942). In the modern context, epigenetics is 
defined as mitotically heritable phenotypes that are mediated by mechanisms other than 
alteration of DNA sequences (Berger, Kouzarides et al. 2009). These mechanisms affect 
chromatin organization, i.e. the three-dimensional structure of DNA within the nucleus, which in 
turn influences gene expression patterns and resulting phenotypic traits among distinct cell types. 
 Epigenetic modifications are classified into three general categories: DNA methylation, 
histone modifications, and nucleosome positioning. Although the term “epigenetic” refers to the 
inheritance of the mark through at least one mitotic cycle, all of the described epigenetic 
modifications are dynamic to some extent (Berger 2007). We know that DNA methylation patterns 
are first erased and then re-established during early embryonic development, and we understand 
the molecular mechanism of their trans-mitotic inheritance. In contrast, the processes underlying 
the maintenance of histone modifications and nucleosome arrangements through the cell cycle 
are not well understood. In these instances, the marks are termed “epigenetic” due to their 
capabilities to alter gene expression patterns, which are maintained in specific cell lineages. 
 
Histone modifications and nucleosome positioning 
 Histones are the core proteins that comprise nucleosomes, and form the structural basis 
underlying chromatin architecture. Nucleosomes consist of 147 base pairs of DNA wrapped 
around a histone octamer, which contains two copies of each core histone protein (H2A, H2B, 
H3, and H4) (Luger, Mäder et al. 1997). The placement and density of nucleosomes determines 
the relative accessibility of DNA to different transcription factors and enzymes, and thus can 
directly impact gene expression (Jenuwein and Allis 2001). 
 Histone proteins can be altered by covalent posttranslational modifications to their 
charged tails, which protrude from the histone and are thus accessible to various modifying 
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enzymes. These modifications alter the electrostatic charge of the histone tails to induce changes 
in the chromatin structure. Repressive histone modifications create a more compact chromatin 
environment, while activating modifications allow DNA binding factors and other proteins to 
interact with DNA and increase gene expression (Kouzarides 2007). In addition, specific histone 
modifications allow binding of ‘reader’ proteins, which can transmit the charged histone state into 
altered gene actions. There are many types of histone modifications and corresponding enzymes. 
For the purpose of this review, we have chosen the most commonly profiled modifications 
described in the current literature. 
 
Activating histone modifications 
There are multiple histone modifications that distinguish active areas of chromatin, but 
the most commonly found at actively transcribed genes are tri-methylation of H3K4 (H3K4me3) at 
their transcription start sites (Kim, Barrera et al. 2005), and H3K36 (H3K36me3) within gene 
bodies (Barski, Cuddapah et al. 2007). The H3K4me3 mark is established by SET-domain 
proteins, including the well-characterized MLL protein (Krivtsov and Armstrong 2007). MLL is a 
mammalian homologue of the Drosophila Trithorax complex, and is a target for translocations in 
acute myeloid leukemia (Thirman, Gill et al. 1993, Krivtsov and Armstrong 2007). MLL contains a 
SET domain responsible for methylation of H3K4 to the mono-, di-, and trimethylated state 
(H3K4me1, me2, me3), and associates with the WDR5, RBPB5, and ASH2L proteins, which are 
necessary for MLL targeting and function (Krivtsov and Armstrong 2007). H3K36me3 marks 
exons within actively transcribed genes, and specifically functions to prevent aberrant RNA 
polymerase activity within active genes (Venkatesh, Smolle et al. 2012). In addition, the 
H3K36me3 intergenic mark contributes to DNA mismatch repair (Li, Mao et al. 2013) and 
alternative splicing (Luco, Pan et al. 2010). 
Enhancers are distal cis-regulatory elements that can be bound by sequence-specific 
DNA-binding transcription factors to activate a given target gene, and are also associated with 
multiple histone modifications. Active enhancers are characterized by H3K27 acetylation 
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(H3K27Ac) (Creyghton, Cheng et al. 2010), which is established by both the CREB binding 
protein (CBP) and p300 acetyltransferases (Tie, Banerjee et al. 2009). H3K4me1and H3K4me2 
also mark cis-regulatory elements such as enhancers and promoters, but do not necessarily 
denote active transcription (Ong and Corces 2011). Interestingly, enhancers are also frequently 
sites of reduced DNA methylation (Lister, Pelizzola et al. 2009, Stadler, Murr et al. 2011, Ziller, 
Gu et al. 2013, Sheaffer, Kim et al. 2014), indicative of cross-talk between histone modifications 
and DNA methylation machinery (see below). 
 
Repressive histone modifications 
The two most commonly profiled repressive histone methylation marks are H3K27me3 
and H3K9me3. H3K27me3 is established by the Polycomb repressive complex 2 (PRC2), 
comprised of the catalytic subunits EZH1 and EZH2, in addition to core subunits SUZ12, EED 
and RBBP7/4 (Margueron and Reinberg 2011). H3K27me3 is regarded as a stable histone 
modification (Zee, Levin et al. 2010), and is widely distributed in ES cell chromatin (Peters, 
Kubicek et al. 2003). PRC2 and H3K27me3 are responsible for silencing key lineage-specific 
regulators in mouse ES cells to repress differentiation processes and maintain pluripotency 
(Boyer, Plath et al. 2006). Depletion of EZH2 and EED in mouse ES cells impairs mesendoderm 
differentiation (Shen, Liu et al. 2008), and deletion of SUZ12, EZH2, or EE causes severe 
gastrulation defects during embryogenesis (Faust, Schumacher et al. 1995, O'Carroll, Erhardt et 
al. 2001, Pasini, Bracken et al. 2007), demonstrating the critical function of PRC2 in 
developmental and differentiation processes.  
The H3K9me3 mark is considered a hallmark of constitutive heterochromatin and is 
regulated by the SUV39H family of methyltransferases, including G9a, SUV39H1/2, and 
SETDB1/2. SUV39H1/2 establish the H3K9me3 mark in heterochromatin (Peters, Kubicek et al. 
2003), where its interaction with heterochromatin protein 1 (HP1) recruits additional SUV39H1/2 
methyltransferases to promote gene silencing (Margueron and Reinberg 2010). SETDB1 is highly 
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expressed in ES cells, and is required to maintain pluripotency and self-renewal capabilities in 
vitro (Bilodeau, Kagey et al. 2009). 
 
Nucleosome Positioning 
 Nucleosome remodeling complexes can completely alter the three-dimensional structure 
of chromatin by the addition, subtraction, or remodeling of nucleosome subunits. These dynamic 
activities are regulated by four families of proteins: SWI/SNF, ISWI, CHD, and INO80 (Portela 
and Esteller 2010). These families of proteins assemble into large complexes, allowing them to 
alter nucleosome position within the larger context of histone modifications and DNA methylation 
patterns. All four types of complexes interact with multiple proteins, including nucleosomes, 
specific histone modifications, chromatin remodeling enzymes, and transcription factors. In 
addition, these remodelers all contain a catalytic subunit with a DNA-dependent ATPase domain, 
which uses the energy from ATP hydrolysis to remodel nucleosomes (Portela and Esteller 2010). 
The ATPases BRM and BRG1 are members of the SWI/SNF family, and share sequence 
homology with the Drosophila Trithorax genes (Schuettengruber, Martinez et al. 2011). BRM and 
BRG1 form multi-protein BAF remodeling complexes, which show a surprising amount of tissue 
and cell-type specificity via differential inclusion of BAF protein subunits (Lessard and Crabtree 
2010). Neural progenitors require BAF45a/53a subunits to support proliferation, while 
differentiation to postmitotic neurons necessitates BAF45b/45c/53b (Lessard, Wu et al. 2007). 
The SWI/SNF family is widely known as a master regulator of gene expression, having roles in 
various pathways related to cell adhesion, alternative splicing, cell cycle regulation and 
differentiation (Reisman, Glaros et al. 2009). Several members, including BRG1 and SNF5, are 
frequently mutated or silenced in various types of cancers, pointing to a possible function as a 
tumor suppressor (Clapier and Cairns 2009).  
The CHD family of nucleosome remodelers is defined by ATPase proteins with 
chromodomains, which bind methylated lysine residues in histone tails (Lessard, Wu et al. 2007). 
CHD3/4 ATPases are essential for nucleosome remodeling activity in the Mi-2/NuRD complex. 
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Mi-2/NuRD also contains the MBD3 protein, which binds methylated DNA, and histone 
deacetylases HDAC1 and HDAC2, which deacetylate histones and tighten local chromatin 
structure (Xue, Wong et al. 1998, Wade, Gegonne et al. 1999, Zhang, Ng et al. 1999). In ES 
cells, Mi-2/NuRD deacetylates H3K27 to promote PRC2-mediated transcriptional repression, 
which is required for ES cell pluripotency and differentiation (Kaji, Caballero et al. 2006, 
Reynolds, Salmon-Divon et al. 2012). Overall, Mi-2/NuRD regulates transcriptional activity by 
coupling histone deacetylation with increased nucleosome density, which alters interactions with 
other histone modifying proteins.  
 
DNA methylation  
DNA methylation refers to the covalent addition of a methyl group to a cytosine base, 
referred to as 5-methylcytosine (5mC), and commonly occurs in the context of a CpG 
dinucleotide. CpG dinucleotides are underrepresented in the mammalian genome due to the 
spontaneous deamination of 5mC to thymine. As a result of these processes, only 1% of the 
human genome consists of CpG sites as opposed to the ~4 percent expected by chance, and 
approximately 60-80% of these CpG sites are methylated, depending on the cell type (Smith and 
Meissner 2013). The remaining unmethylated CpGs are predominantly located in regions of 
increased CpG frequency, termed CpG islands (CGIs). CGIs, as defined by Takai and Jones 
(2002), are ≥ 500 base pairs in length, have a CpG observed/expected ratio ≥0.65, and have at 
least 55% GC content. CGIs are generally unmethylated, and are located at 72% of annotated 
promoters in the human genome (Saxonov, Berg et al. 2006). Interestingly, regions of low CpG 
methylation can also be found for distal CGIs in enhancers (Lister, Pelizzola et al. 2009, Stadler, 
Murr et al. 2011, Ziller, Gu et al. 2013).  
 The enzymes that establish DNA methylation patterns are DNA methyltransferases 
(DNMT). There are three DNMTs encoded in the mammalian genome, divided into two categories 
based on their sequence similarities and DNA methyltransferase activities in vitro. The “de novo” 
methyltransferases, DNMT3A and DNMT3B, have low affinity for hemi-methylated compared to 
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unmethylated DNA in vitro (Okano, Xie et al. 1998), and can establish novel patterns of DNA 
methylation. The second type of DNMT is the “maintenance” methyltransferase DNMT1. DNMT1 
associates with factors at the replication fork to copy patterns of methylation onto newly 
synthesized strands of DNA, thereby faithfully maintaining the pattern of DNA methylation across 
multiple cell divisions (Leonhardt, Page et al. 1992). It has recently been suggested that the 
categories of “maintenance” and “de-novo” are too simplistic to describe the complex interplay of 
DNMT activity in vivo (Jones and Liang 2009). For example, deletion of Dnmt1 in mouse ES cells 
causes only a 66% decrease in DNA methylation levels (Li, Bestor et al. 1992), suggesting that 
DNMT3A and DNMT3B have some maintenance methyltransferase activity.  
DNA methylation and therefore DNMTs are crucial for mammalian development. Dnmt1- 
or Dnmt3b-null mouse embryos arrest at E.9.5, and Dnmt3a-null newborn mice are runted and 
die within the first two weeks of life (Li, Bestor et al. 1992, Okano, Bell et al. 1999). Intriguingly, 
triple Dnmt-knockout (TKO) mouse ES cells have normal morphology and survival in vitro, but 
undergo apoptosis when induced to differentiate (Jackson, Krassowska et al. 2004, Tsumura, 
Hayakawa et al. 2006). In contrast, recent studies have shown that human ES cells require 
DNMT1 even during maintenance culture (Liao, Karnik et al. 2015). These results support the 
notion that mouse and human ES cells denote distinct pluripotent states, with human ES cells 
representing a later stage of epiblast development relative to mouse ES cells (Nichols and Smith 
2009). Overall, these data strongly implicate a critical role for DNA methylation in early embryonic 
development and differentiation processes. 
Differential methylation patterns distinguish specific tissue and cells types, with 
differential methylation occurring at CGI shores and enhancer elements (Irizarry, Ladd-Acosta et 
al. 2009, Stadler, Murr et al. 2011, Ziller, Gu et al. 2013). DNA methylation acts primarily as a 
repressive epigenetic modification in chromatin, downregulating expression of genes associated 
with regions of increased DNA methylation. There are two broad means by which DNA 
methylation can repress gene expression: direct inhibition of DNA binding transcription factors, 
and interactions with other chromatin remodeling enzymes to promote a repressive chromatin 
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environment. Although several examples of direct inhibition of transcription factor binding to 
methylated DNA are known, including for CREB, AP-2, and E2F (Tate and Bird 1993), the 
majority of studies have focused on how DNA methylation patterns influence global chromatin 
organization. The effects of DNA methylation on chromatin may be indirect, such as through the 
methyl CpG binding proteins MeCP2, MBD2, or MBD3. MeCP2 recruits histone deacetylases to 
methylated DNA, which promotes heterochromatin formation and stable gene repression (Jones, 
Veenstra et al. 1998, Nan, Ng et al. 1998). Additionally, the DNMTs directly interact with several 
chromatin-remodeling complexes, such as Polycomb group protein EZH2, to facilitate 
heterochromatin formation (Viré, Brenner et al. 2006). 
Histone modifications, such as the repressive H3K9me, can be recognized by DNMTs to 
influence heterochromatin formation and nucleosome remodeling. G9a dimethylates H3K9, which 
creates a binding site for heterochromatin protein 1 (HP1). HP1 then recruits DNMT1, which 
methylates CpGs to support permanent transcriptional repression (Estève, Chin et al. 2006, 
Smallwood, Estève et al. 2007). Interestingly, binding to DNMT1 also stabilizes localization of 
HP1, allowing HP1 to recruit other chromatin remodeling complexes to form highly structured 
heterochromatin (Estève, Chin et al. 2006, Smallwood, Estève et al. 2007). In cancer, both HP1 
and DNA methylation levels are globally reduced, signifying the importance of epigenetic cross 
talk in disease progression (Feinberg and Vogelstein 1983, Gama-Sosa, Slagel et al. 1983, 
Dialynas, Vitalini et al. 2008). 
DNA methylation has long been considered the most “stable” of the epigenetic 
modifications. The earliest studies of DNA methylation and DNMT function described the 
processes of imprinting and X-chromosome inactivation during development (Holliday and Pugh 
1975, Venolia and Gartler 1983, Bartolomei, Zemel et al. 1991). Imprinting refers to the 
phenomenon of monoallelic gene expression in a parent-of-origin specific manner. One of the 
best-understood examples of imprinting occurs at the H19/IGF2 locus, in which differential 
methylation at the imprinting control region (ICR) located between the two genes determines 
monoallelic H19 and IGF2 expression. The ICR is methylated on the paternal allele, which results 
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in IGF2 expression from the paternal chromosome and H19 expression from the maternal 
chromosome (Li, Beard et al. 1993). Imprints are maintained in all mature somatic cells types, 
and are only erased during primordial germ cell development in embryogenesis (Plasschaert and 
Bartolomei 2014).   
 
The mammalian intestinal epithelium 
One of the aims of epigenetic research is to elucidate how the various marks interact with 
one another, and which components are essential to disease progression and prevention. To 
study chromatin dynamics in vivo, during development as well as homeostasis and disease 
progression, requires a model system that closely parallels its human counterpart but is still 
genetically tractable. The mouse intestinal epithelium fits these requirements, and is an excellent 
model for the study of chromatin in modulating gene expression and disease. The structural 
components of the mouse intestinal epithelium are strikingly similar to those of the human 
intestine. Models for human intestinal disease, including colorectal cancer and inflammatory bowl 
disease, are well established in the mouse, which permits studies of chromatin marks and 
complexes in disease progression. The precise mechanisms that regulate intestinal epithelial 
homeostasis and disease have remained elusive, and it is possible that epigenetic marks play a 
crucial role in such processes. 
The adult intestinal epithelium consists of a single layer of columnar cells lining the lumen 
of the intestine. The epithelium is structured into crypts that invaginate into the underlying 
mesenchyme, and villi that project into the intestinal lumen (Figure 1.1). In intestinal homeostasis, 
the crypt-based columnar (CBC) stem cells give rise to rapidly dividing transit-amplifying crypt 
cells. As the transit amplifying cells exit the crypt, they differentiate into one of five major cell 
types: absorptive cells, called enterocytes, goblet cells, enteroendocrine cells, Paneth cells 
(Cheng and Leblond 1974), and Tuft cells (Gerbe, Legraverend et al. 2012). Paneth cells are 
retained at the base of the crypt, while the other types of differentiated cells migrate up the villi. 
Differentiated cells migrate in ordered cohorts along the villi as more cells are produced, and 
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reach the top of the villus after 3-5 days, at which point the cells apoptose and are shed into the 
intestinal lumen. This high rate of cellular turnover indicates tight regulation of cell proliferation 
and differentiation processes. Indeed, misregulation of intestinal crypt proliferation is the hallmark 
of intestinal and colorectal cancer (Fearon 2011). 
 
The intestinal stem cell niche and Wnt signaling 
Crypts form the intestinal stem cell niche, and harbor two well-characterized populations 
of stem cells (Figure 1.1). The first are the crypt-based-columnar (CBC) stem cells, which express 
the markers Lgr5 and Olfm4, and give rise to all cell types in the intestinal epithelium (Barker, van 
Es et al. 2007, van der Flier, Haegebarth et al. 2009). CBCs are considered the active population 
of intestinal stem cells, and divide approximately once every 24 hours. The second population of 
stem cells are the quiescent “+4 stem cells,” marked by Bmi1, Tert, and Hopx (Barker, van 
Oudenaarden et al. 2012). The +4 stem cells constitute a reserve population; upon ablation of the 
CBC population in mice, +4 stem cells can give rise to new CBC stem cells and repopulate the 
intestinal epithelium (Tian, Biehs et al. 2011). In separate studies, it was also shown that the CBC 
cells can give rise to +4 stem cells (Takeda, Jain et al. 2011). As a result, it is difficult to make a 
clear distinction between the two interconverting stem cell populations. It is possible that the crypt 
base contains a equipotent population of intestinal stem cells, and that the cell position within the 
crypt determines whether the cell is a fast- or slow-dividing stem cell. Evidence supporting this 
equipotent stem cell hypothesis comes from studies of irradiated mice, in which Dll1+ secretory 
precursors can convert to Lgr5+ CBCs to compensate for epithelial loss (van Es, Sato et al. 
2012).  
The main signaling pathway that supports proliferation in the crypt, both in vivo and in 
vitro, is the canonical Wnt signaling pathway. Briefly, canonical Wnt signaling depends on 
cytoplasmic stabilization of β-catenin, via disassociation of the Gsk3β-APC-Axin destruction 
complex. Accumulation of stable β-catenin protein in the cytoplasm results in its translocation to 
the nucleus, where it interacts with Tcf/Lef DNA binding effector proteins at target genes to 
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activate transcription. Wnt activity is required to maintain proliferation in the adult intestinal crypt; 
overexpression of the secreted Wnt antagonist Dkk1 in mouse intestinal epithelium inhibits 
proliferation, and blocks formation and maintenance of crypts (Pinto, Gregorieff et al. 2003, 
Kuhnert, Davis et al. 2004). Deletion of Tcf4, the main β-catenin nuclear effector in mouse 
intestinal epithelium, causes complete loss of proliferation and stem cell identity in the adult 
intestine, and mice die ~9 days following ablation (Korinek, Barker et al. 1998). 
Paneth cells are proposed to have an active role in maintaining the CBC stem cells 
through their secretion of Wnt ligands (Sato, van Es et al. 2011). This hypothesis was supported 
by observations that single Lgr5+ cells grow more efficiently in vitro when paired with a Paneth 
cell (Sato, van Es et al. 2011). However, ablation of Paneth cells has no deleterious effects on 
CBC homeostasis or crypt architecture in adult mice (Durand, Donahue et al. 2012), suggesting 
there are redundant mechanisms to maintain proliferation and Wnt signaling in vivo. Inhibiting 
Wnt ligand secretion concurrently in Paneth cells and subepithelial myofibroblasts did not alter 
crypt proliferation or crypt-villus architecture in adult mice (San Roman, Jayewickreme et al. 
2014). However, there is some evidence that supports a critical role for the mesenchyme in 
maintaining the intestinal stem cell niche. Kabiri and colleagues inhibited epithelial Wnt secretion, 
and demonstrated that epithelial Wnt ligands are not required for crypt maintenance during 
development, homeostasis, or following injury (2014). Interestingly, ex vivo organoid cultures from 
these mice illustrated a dependence on exogenous Wnt sources. The authors reported that co-
culture with wild-type intestinal stromal cells negated the requirement for supplementation with 
Wnt factors, strongly suggesting that the niche supporting cells exist within the intestinal stroma 
(Kabiri, Greicius et al. 2014). Thus, there are many populations of distinct mesenchymal cells 
surrounding the intestinal epithelium, and it is likely that one of these cell types is supporting the 
intestinal crypt. 
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Differentiation in the intestinal epithelium 
There are five main types of differentiated cells in the intestinal epithelium: absorptive 
enterocytes, goblet cells, Paneth cells, enteroendocrine cells, and Tuft cells (Figure 1.1). 
Although enterocytes comprise ~90% of the intestinal villi cell population (Cheng and Leblond 
1974), the other types of differentiated cells secrete proteins that are crucial to intestinal function 
and survival. Goblet cells secrete mucin, the main component of mucus and the intestinal 
epithelial barrier, and are important to protect against potential pathogens in the lumen. Mucus 
coats the entire intestinal epithelium, acting as a lubricant to promote digestion, and preserves 
the structure of the epithelium upon physical force or injury (van der Flier and Clevers 2009). 
Enteroendocrine cells secret various hormones, including glucagon-like peptides 1 and 2 (GLP-1, 
-2), cholecystokinin (CCK), Glucose-dependent insulinotropic peptide (GIP), and somatostatin 
(SST) (Lee and Kaestner 2004). There are ~15 types of enteroendocrine cells, and their secreted 
hormones have important functions in feeding behavior, satiation, and glucose homeostasis 
(Cummings and Overduin 2007). For instance, GLP-1 is released in the small intestine following 
food intake, and promotes glucose uptake by stimulating pancreatic β-cell insulin secretion 
(Kreymann, Williams et al. 1987, Mojsov, Weir et al. 1987).   
Paneth cells are distinct from the other types of differentiated cells. As they differentiate 
from the transit-amplifying pool, they migrate to the base of the crypt and reside interspersed 
between the CBC stem cells (Figure 1.1). Paneth cells are long-lived relative to villus cell 
populations, surviving for approximately one month in the crypt epithelium (Troughton and Trier 
1969). Their main function is to secrete lysozyme and other defensin proteins that protect against 
bacterial infection in the epithelium (Porter, Bevins et al. 2002).   
Another type of endocrine cell, the Tuft cell, comprises 0.4% of the intestinal epithelium 
(Gerbe, Legraverend et al. 2012) and has garnered much attention over the past five years due to 
the discovery of their distinct cell lineage. Although they require the pan-endocrine transcription 
factor Atoh1 for differentiation, Tuft cells do not require the other factors necessary for 
enteroendocrine, goblet, or Paneth cell specification (Gerbe, van Es et al. 2011). Tuft cells are 
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marked by expression of Dclk1, and have been shown to contribute to intestinal recovery 
following injury (Gerbe, Brulin et al. 2009, Westphalen, Asfaha et al. 2014). Dclk1 is also a 
putative cancer stem cell marker, and loss of Dclk1+ cells abrogates tumorigenesis on the ApcMin/+ 
colorectal cancer mouse model (May, Riehl et al. 2008, Nakanishi, Seno et al. 2013). 
 
Notch signaling regulates differentiation and stem cells 
Notch is one of the most important signaling pathways in the intestinal epithelium, and 
has crucial roles in regulating both intestinal proliferation and differentiation processes. The Notch 
signaling pathway works via lateral inhibition, in which one cell expressing the Delta ligand 
activates the Notch receptor on an adjacent cell. Activation of the Notch receptor causes 
cleavage of its intracellular domain, which subsequently translocates to the nucleus and forms a 
complex with the DNA-binding transcription factor CSL (CBF-1/RBP-Jκ, Su(H), Lag-1). CSL 
normally acts to repress gene expression, but binding of the Notch intracellular domain (NICD) 
converts CSL to a transcriptional activator. In the intestinal epithelium, secretory precursors 
expressing the Delta ligand (Dll) activate Notch signaling in neighboring cells. NICD activity 
increases expression of the bHLH transcription factor Hes1, which supports enterocyte 
differentiation via its repression of Atoh1 (Jensen, Pedersen et al. 2000, Zheng, Tsuchiya et al. 
2011). Atoh1 is a bHLH transcription factor necessary (Yang, Bermingham et al. 2001, Shroyer, 
Helmrath et al. 2007) and sufficient (VanDussen and Samuelson 2010) for all secretory lineages 
in the intestinal epithelium. Notch signaling opposes Atoh1 activation to direct cell fate into the 
enterocyte lineage. Loss of Notch signaling causes increased secretory cell differentiation along 
the crypt-villus axis, either through use of γ-secretase inhibitors (van Es, van Gijn et al. 2005, 
VanDussen, Carulli et al. 2012), or by ablation of Notch receptors (Riccio, van Gijn et al. 2008, 
Carulli, Keeley et al. 2015), Dll ligands (Pellegrinet, Rodilla et al. 2011), or CSL/RBP-Jκ (van Es, 
van Gijn et al. 2005). Combined loss of Notch signaling and Atoh1 expression blocks secretory 
cell fate conversion and induces global enterocyte differentiation (Kazanjian, Noah et al. 2010, 
van Es, de Geest et al. 2010, Kim and Shivdasani 2011, VanDussen, Carulli et al. 2012), 
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establishing that Notch acts specifically through that Atoh1 to regulate secretory cell fate, and that 
active Notch is not required for enterocyte differentiation. Conversely, mice with forced over-
expression of Notch ICD display severe reduction of secretory cell types and increased 
enterocyte differentiation (Fre, Huyghe et al. 2005, Stanger, Datar et al. 2005). 
Interestingly, over-expression of the NICD causes increased crypt cell proliferation (Fre, 
Huyghe et al. 2005, Stanger, Datar et al. 2005), whereas loss of Notch signaling blocks 
proliferation and converts crypt cells to secretory cell fates (van Es, van Gijn et al. 2005, Riccio, 
van Gijn et al. 2008, Pellegrinet, Rodilla et al. 2011, VanDussen, Carulli et al. 2012). Notch 
pathway inhibition decreases expression of CBC stem cell marker genes, including Olfm4 and 
Lgr5 (Pellegrinet, Rodilla et al. 2011, VanDussen, Carulli et al. 2012, Carulli, Keeley et al. 2015). 
VanDussen and colleagues found that the NICD directly activates expression of Olfm4, 
demonstrating the crucial function of Notch signaling in maintaining the CBC stem cell population 
(2012).  
Notch signaling components are expressed in the crypt, and interact with Wnt signaling to 
support stem cell renewal, proliferation, and differentiation processes (Noah and Shroyer 2013). 
In fact, Wnt activation strongly favors a secretory cell fate by its positive regulation of Atoh1 and 
Sox9 (Pinto, Gregorieff et al. 2003, Blache, van de Wetering et al. 2004), important for Paneth 
cell fate, and mouse models with decreased Wnt signaling display reduced numbers of secretory 
cells (Korinek, Barker et al. 1998, Pinto, Gregorieff et al. 2003). Activation of Notch in the Tcf4-
null, non-proliferative developing intestinal epithelium fails to restore progenitor cell division (Fre, 
Pallavi et al. 2009). A recent report from Tian et al. (2015) used Notch-inhibiting antibodies to 
illustrate that Notch inhibition allows increased Wnt-activation of secretory genes, such as 
lysozyme, at the expense of crypt cell proliferation. Concurrent treatment with both Wnt- and 
Notch-blocking antibodies restored CBC proliferation and normal cell differentiation, suggesting 
that Notch mediates its effects in part through Wnt pathway inhibition (Tian, Biehs et al. 2015). 
These experiments demonstrate that cooperation between Notch and Wnt signaling is crucial to 
maintain proliferation and differentiation processes in the intestinal epithelium. 
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Crypt-villus organization: Hedgehog and BMP 
 The architecture of the intestinal epithelium is tightly regulated, and misregulation of 
crypt-villus organization is a step in disease progression. There are several signaling pathways 
essential for maintaining the crypt-villus axis demarcation. Many of these signals are active during 
intestinal development, and require cross talk between the intestinal epithelium and the 
surrounding mesenchymal tissue. 
 The Hedgehog ligands Sonic hedgehog (Shh) and Indian hedgehog (Ihh) are expressed 
in developing epithelium, and become restricted to proliferative regions as development 
progresses (Ramalho-Santos, Melton et al. 2000). The Hedgehog receptors, Patched, and their 
effectors, the Gli transcription factors, are expressed in the underlying mesenchyme (Ramalho-
Santos, Melton et al. 2000). Hedgehog signaling during intestinal development becomes active 
upon binding of epithelial Hh ligands to Patched receptors expressed in intestinal mesenchyme. 
Hedgehog (Hh) ligand binding to Patched relieves inhibition of Smoothened, which activates Gli 
transcription factors; Gli then translocates to the nucleus, where it regulates expression of Hh 
target genes. Expression of the pan-Hh inhibitor Hhip in the developing intestinal epithelium 
impairs villus morphogenesis and increases Wnt signaling, resulting in flattened hyper-
proliferative intestinal epithelium (Madison, Braunstein et al. 2005).  
The Hhip-mice also display disorganization of myofibroblasts normally associated with 
crypt epithelium, and significantly decreased BMP ligand expression within the intestinal 
mesenchyme (Madison, Braunstein et al. 2005). Similar to Hedgehog, BMP signaling also 
requires crosstalk between the mesenchyme and epithelium. In this situation, however, the BMP 
ligands are expressed in the mesenchyme, and the receptors are expressed in the epithelium 
(Haramis, Begthel et al. 2004). During intestinal development, the BMP ligands are expressed in 
clusters of mesenchymal cells underlying putative villi (Karlsson, Lindahl et al. 2000), and the 
highest levels of BMP signaling are observed in villi (Madison, Braunstein et al. 2005). When the 
BMP antagonist Noggin is overexpressed in intestinal epithelium (Haramis, Begthel et al. 2004, 
Batts, Polk et al. 2006), or if the BMP receptor is ablated (He, Zhang et al. 2004), irregular hyper-
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proliferative crypt structures appear throughout the epithelium, confirming a role for BMP in 
supporting villus formation and repressing crypt development. It has been posited that epithelial 
Hedgehog signals promote mesenchymal BMP activation, and that both pathways antagonize 
one another to ensure proper crypt and villus formation (Roberts, Johnson et al. 1995, Roberts, 
Smith et al. 1998, Sukegawa, Narita et al. 2000, Ishizuya-Oka, Hasebe et al. 2006). However, 
direct activation of BMP signaling by Hedgehog has not been demonstrated in the mammalian 
intestinal epithelium in vivo. 
The Foxl1 transcription factor is highly expressed in intestinal mesenchyme (Kaestner, 
Bleckmann et al. 1996), and regulates the transition from pseudostratified to columnar epithelium 
during intestinal epithelial development. Ablation of Foxl1 results in delayed crypt-villus 
morphogenesis, and abnormal proliferation patterns in late fetal stages and the first two weeks of 
life (Kaestner, Silberg et al. 1997). Foxl1 is also a bona-fide Hedgehog target gene, and contains 
several highly conserved Gli binding sites near its promoter (Madison, McKenna et al. 2009). 
Interestingly, BMP ligand expression is decreased in developing Foxl1-mutant intestinal 
mesenchyme (Kaestner, Silberg et al. 1997), suggesting that Foxl1 may be the link modulating 
BMP and Hedgehog signals between epithelial and mesenchymal cells (Madison, McKenna et al. 
2009).  
 
Transcriptional and Epigenetic Regulation of the Intestinal Epithelium 
 The genetics of key DNA binding transcription factors in the intestinal epithelium has 
been extensively studied, but less is known about the role of chromatin marks and mediators in 
the processes of intestinal homeostasis. Two conflicting viewpoints have emerged over the past 
decade (Figure 1.2). The first is the concept that the chromatin of the intestinal epithelium is 
largely permissive, and that transcription factor activity is the defining characteristic that alters 
gene expression patterns (Figure 1.2 A-B). The second posits that the chromatin itself plays an 
important role in regulating gene expression, and that chromatin states are not necessarily 
dependent on transcription factor activity (Figure 1.2 C-D). 
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Transcription factors regulate open chromatin and intestinal homeostasis 
There are several transcription factors that are globally important for intestinal epithelial 
development, maintenance, and proliferation. Cdx2 is master-regulator of intestinal epithelial 
differentiation, and is essential for the specification of all intestinal epithelia during mouse 
endoderm development (Gao, White et al. 2009). Cdx2 ablation in mouse endoderm prevents 
colon and rectum morphogenesis and causes global defects in differentiation and proliferation 
transcriptional programs (Gao, White et al. 2009). Cdx2 is also required for normal activation of 
pro-intestine transcription factors, including Hnf1α, Hnf4 α, and Cdx1, and regulates Hedgehog 
ligand secretion from the epithelium to the underlying mesenchyme (Gao, White et al. 2009). 
Loss of Cdx2 at mid-gestation perturbs apical-basolateral polarity of the developing epithelium, 
causing deficient enterocyte development and maintenance (Gao and Kaestner 2010). In 
addition, inducible deletion of Cdx2 in the adult gut reduces villus length and the numbers of 
enterocytes, causing nutrient malabsorption and death within three weeks (Verzi, Shin et al. 
2010, Verzi, Shin et al. 2011). Each of these studies demonstrated that Cdx2 is capable of both 
transcriptional repression and activation, based on gene expression changes following Cdx2 loss 
(Gao, White et al. 2009, Gao and Kaestner 2010, Verzi, Shin et al. 2011).  
To study the CDX2 binding dynamics during intestinal cell differentiation, Verzi and 
colleagues first utilized the Caco-2 human cell line, which can be manipulated to produce 
homogeneous populations of proliferative and differentiated intestinal cells. They performed 
H3K4me2, H3K27ac, and CDX2 ChIP-Seq to demonstrate that CDX2 binds distinct cis-regulatory 
sites in differentiated and proliferative cell states (Figure 1.2 A-B) (Verzi, Shin et al. 2010). In the 
same model system, they showed that CXD2 preferentially co-localizes with GATA6 at enhancer-
marked chromatin in proliferative cells, and HNF4α at different enhancer elements in 
differentiated cell populations (Figure 1.2 B) (Verzi, Shin et al. 2010). In differentiated mouse villi, 
Verzi and colleagues found that Cdx2 co-localized with Hnf4α at many distal enhancer elements, 
which they defined as 450-600 bp regions flanked by H3K4me2-marked nucleosomes (Figure 1.2 
B) (2013). Loss of Cdx2 in mouse intestinal villi reduced HNF4α binding at co-bound sites (Verzi, 
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Shin et al. 2013), in agreement with previous data showing that Cdx2 regulates Hnf4α expression 
(Gao, White et al. 2009). Interestingly, they also discovered that Cdx2-bound sites displayed 
reduced H3K4me2 nucleosome occupancy in Cdx2-deficient villi, and conclude that Cdx2 is 
required to maintain open chromatin in differentiated cells (Verzi, Shin et al. 2010, Verzi, Shin et 
al. 2013). These findings build upon previous work that established Cdx2 as the master-regulator 
of intestinal epithelial differentiation (Gao, White et al. 2009, Gao and Kaestner 2010), and 
suggest that Cdx2 exerts this function both by its ability to control chromatin compaction and 
through its interactions with multiple transcription factors. 
Based on the above data, it appears that Cdx2 maintains the intestinal epithelium in a 
largely active chromatin state (Figure 1.2 A-B). These conclusions are supported by additional 
studies that more thoroughly analyzed histone marks during in vivo differentiation. Through 
advanced genetic and cell sorting techniques it is possible to isolated various populations of cells 
from the adult mouse intestine, including the Lgr5+ stem cells, secretory progenitors, and 
enterocyte progenitors. Kim and colleagues performed H3K4me2 and H3K27ac ChIP-Seq, 
DNAseI mapping, and RNA-Seq to define the different cell populations by their open chromatin 
states and associated gene expression (2014). Although the stem cells, secretory progenitors, 
and enterocytes display distinct transcript profiles, the enterocyte and secretory progenitor 
populations have remarkably similar H3K27ac, H3K4me2, and DNAseI profiles, which indicate 
active enhancer elements and globally open chromatin structure (Kim, Li et al. 2014). The authors 
propose that DNA-binding factors influence chromatin activity during the differentiation process, 
and that the labile chromatin structure renders progenitors capable of reacting to the available set 
of transcription factors. To test this hypothesis, they attempted to direct progenitor cell fate in vivo 
by genetic manipulation of lineage-specific transcription programs. Acute inhibition of Notch 
signaling forces progenitors to adopt a secretory cell fate within two days. Following global 
conversion of progenitors to secretory cell fate, the authors induced loss of Atoh1, which is 
completely required for secretory lineages. As the authors predicted, secretory progenitors 
present at the outset of Atoh1 deletion convert to enterocyte fates (Kim, Li et al. 2014). They 
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concluded that the dynamic abilities of progenitor cells to convert lineages is due to their similar 
chromatin profiles, and that expression of distinct transcription factors specifies cell fate.  
Additional work has characterized the function of the H3K79 methyltransferase DOT1L in 
the mouse intestinal epithelium. H3K79me2 is associated with both heterochromatin and 
euchromatin in model organisms and has known functions in transcriptional elongation, cell cycle 
checkpoints, and DNA repair (Nguyen and Zhang 2011). DOT1L-mediated gene activation is 
commonly employed in human leukemias with MLL translocations, making DOT1L an attractive 
target in disease research (Okada, Feng et al. 2005). Two recent studies analyzed the 
requirements for DOT1L and H3K79me, and reported strikingly different results. 
Mahmoudi and colleagues originally identified Mllt10/Af10 in a screen for proteins that 
bind directly to the Tcf4/Wnt-signaling complex in the mouse intestinal epithelium (2010). 
MLLT10/AF10 directly interacts with the DOT1L methyltransferase to promote transcriptional 
activation, and is the primary mechanism by which DOT1L is activated in human leukemia 
(Okada, Feng et al. 2005, Nguyen and Zhang 2011). The authors report that DOT1L and the 
Mllt10/Af10 mediators are essential for Wnt target activation in intestinal crypts (Mahmoudi, Boj et 
al. 2010). However, these conclusions were only validated at Axin and C-myc, two canonical Wnt 
target genes.  
A comparable study from an independent research group also evaluated the function of 
DOT1L in the intestinal epithelium, with different results (Ho, Sinha et al. 2013). They profiled 
H3K79me2 and RNA expression levels in villi and crypts isolated from adult mouse intestine. 
Surprisingly, the authors demonstrate similar levels of H3K79me2 at various Wnt targets in both 
crypt and villus compartments. They do note that H3K79me2 generally correlates with increased 
expression of associated genes, for both Wnt and non-Wnt target genes. Ablation of DOT1L in 
the intestinal epithelium caused global loss of H3K79me, but did not have any deleterious effects 
on differentiation or crypt-villus morphology. Indeed, Wnt targets were expressed at normal levels 
in the absence of DOT1L, indicating that the H3K79me2 mark is not essential for intestinal 
epithelial gene activation (Ho, Sinha et al. 2013). Ho and colleagues clearly demonstrate that 
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DOT1L-mediated H3K79me2 associates with transcribed genes both in crypts and villi, and is not 
required for Wnt target gene activation in intestinal crypt cells (2013).  
Overall, these studies suggest that the chromatin landscape of the intestinal epithelium is 
largely accessible, particularly at enhancer and regulatory elements. This enhancer chromatin is 
amenable to changes induced by transcription factors, such as Cdx2 and Hnf4α, and allows 
progenitor cells to quickly adapt to specific cell fates. These statements align well with reports of 
plasticity within the intestinal epithelium upon tissue damage (van Es, Sato et al. 2012). However, 
a comprehensive study comparing various repressive and activating histone modifications in 
intestinal epithelial cell sub-populations has not been reported. In the future, it will be important to 
profile multiple histone marks in the stem cell, progenitor, and differentiated cell types in order to 
fully understand the function of chromatin during intestinal homeostasis and disease. 
 
DNA methylation regulates enhancers and intestinal proliferation  
 The second view within the current literature introduced above is that chromatin and its 
associated modifications play a significant role in regulating proliferation and differentiation in the 
intestinal epithelium. This premise closely aligns with the two reports profiling genome-wide 
methylation levels in intestinal Lgr5+ CBC stem cells and differentiated villus cells. Both studies 
reported similar methylomes between stem and differentiated cells, and focused their analyses 
specifically on enhancer regions that have altered DNA methylation between the two cell 
populations.  
In the first published study, the authors note low levels of DNA methylation at the majority 
of transcription start sites, which they suggest primes cells for the process of differentiation. Their 
data analysis required a 40% change in DNA methylation between the two cell populations for 
identification as a differentially methylated region (DMRs), resulting in the discovery of only 50 
DMRs (Kaaij, van de Wetering et al. 2013). The majority of these DMRs lost DNA methylation 
from stem to differentiated cell. Interestingly, these DMRs were positive for H3K4me1 and 
H3K27ac enhancer marks, and several of these putative enhancers loop and make contact with 
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the transcription start site of differentially expressed genes (Kaaij, van de Wetering et al. 2013). 
Many DMRs were also located near Tcf4 binding sites, indicating possible regulation by Wnt 
signaling. Unfortunately, the authors provided only limited in vivo data testing of their hypothesis 
that loss of Tcf4 correlates with higher methylation levels at several DMRs in villi, and suggest 
that Wnt signaling interacts with chromatin to promote DNA demethylation during the 
differentiation process (Kaaij, van de Wetering et al. 2013).  
A second study employed vastly different bioinformatics approaches, resulting in 
identification of considerably more DMRs (Sheaffer, Kim et al. 2014). The authors note that 
modest DNA methylation levels of 13.9-50% identify most enhancer regions (Stadler, Murr et al. 
2011), and suggest that a 40% change in methylation for DMR identification is too strict a 
limitation. Sheaffer and colleagues report that the average change in methylation at DMRs was 
15%, and that these changes were enriched at CGIs and CGI shores (2014). These data align 
with the observations that alterations in CG methylation affecting tissue and cell-specific gene 
expression often occur in CGIs and shores (Irizarry, Ladd-Acosta et al. 2009, Stadler, Murr et al. 
2011, Ziller, Gu et al. 2013). They performed parallel H3K27ac ChIP-Seq and RNA-Seq, and also 
utilized available Cdx2 and Hnf4α ChIP-Seq data (Verzi, Shin et al. 2013)(Verzi, Shin et al. 
2013)(Verzi, Shin et al. 2013)(Verzi, Shin et al. 2013)(Verzi, Shin et al. 2013)(Verzi, Shin et al. 
2013), to correlate DMRs with active enhancer elements during the differentiation process. Many 
DMRs that gained methylation during differentiation associate with highly expressed ISC genes, 
and demonstrate increased H3K27ac and Cdx2 binding in the Lgr5+ population relative to villus 
cells (Figure 1.2 C-D). DMRs that lost methylation from the stem to differentiated cell state 
corresponded with increased expression of the associated gene, which were enriched for 
metabolism and enterocyte-specific transcripts. Interestingly, they discovered that these 
differentiation-DMRs also gained H3K27ac, and displayed increased Cdx2 and Hnf4α binding in 
differentiated cells versus Lgr5+ ISCs (Sheaffer, Kim et al. 2014). These data indicate that DNA 
methylation works in combination with transcription factors to activate enhancers and modulate 
gene expression programs during intestinal differentiation. 
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The authors also employed genetic means to demonstrate that DNA methylation has 
significant effects on cell proliferation and differentiation in vivo. Inducible deletion of Dnmt1 in the 
adult mouse intestine caused an approximately two-fold expansion of the crypt compartment, and 
increased expression of Lgr5 and Olfm4, markers of active CBC stem cells (Sheaffer, Kim et al. 
2014). Targeted bisulfite sequencing upstream of these stem cell genes revealed demethylation 
at putative enhancer elements, implicating a role for Dnmt1 and DNA methylation in promoting 
cell differentiation and restricting crypt cell proliferation (Figure 1.2 C-D) (Sheaffer, Kim et al. 
2014). The above experimental results strongly suggest a role for DNA methylation in regulating 
enhancer activation and controlling processes relating to cell proliferation. 
 
Epigenetic Modifications and Aberrations in Intestinal Disease 
 Colorectal cancer (CRC) is the third most common type of cancer in the United States, 
with a lifetime incidence of approximately 5% in both men and women (Siegel, Desantis et al. 
2014). The risk of developing colorectal cancer increases with age, as 60% of CRC diagnoses 
and 70% of deaths relating to CRC occur in patients at 65 years or older (Siegel, Desantis et al. 
2014). 
 The adenoma to carcinoma progression is well characterized in human CRC, and it may 
take several decades for a malignant tumor to fully form. Cancers begin as hyper-proliferative 
crypts that have accumulated mutations in tumor suppressor genes, such as APC, a Wnt inhibitor 
that is mutated in 80% of sporadic CRCs (Fearon 2011). Loss of APC causes constitutive Wnt 
activation and increased proliferation, resulting in dysplastic crypts. Over time, these hyper-
proliferative foci develop into adenomatous polyps, or adenomas. Adenomas are generally 
benign, but a small percent progress to carcinoma, and adenomatous polyps are the main 
precursor to invasive colorectal cancers (Jass 2007).  
Development from adenoma to carcinoma requires multiple gene mutations; primary 
tumors harbor up to 80 distinct somatic mutations, and as many as 7 major genetic translocations 
or duplications (Wood, Parsons et al. 2007, Leary, Lin et al. 2008). Tumor suppressor proteins, 
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including p53 and PTEN in addition to APC, accumulate inactivating mutations that allow 
unrestrained proliferative activity. Typically, both alleles of a tumor suppressor gene must be 
inactivated to cause a phenotype, following Knudson’s two-hit rule (Fearon 2011). Thus, germline 
inheritance of a heterozygous allele at these genes renders patients sensitive to cancer initiation 
by a loss-of-heterozygosity (LOH) mutation mechanism. Loss of tumor suppressor gene function 
is important in promoting genomic instability, a key feature of most invasive carcinomas. For 
instance, nearly 70% of CRCs display mutations in chromosome 18q (Vogelstein, Fearon et al. 
1988). These mutations inactivate TGF-β signaling, which normally acts to restrict intestinal cell 
proliferation to the crypt. Oncogenic mutations are common in CRC as well, with approximately 
40% of CRCs demonstrating activating mutations at KRAS to support cell division via the EGFR 
pathway (Fearon 2011).  
Sporadic CRCs are separated into two general categories: those with microsatellite 
instability and mismatch repair deficiencies, and those that are microsatellite stable but display 
chromosomal aneuploidy and large-scale genomic alterations (Network 2012). Microsatellite 
instability (MSI) refers to changes in the length of microsatellite repeat elements, and is usually 
caused by defects in the DNA mismatch repair (MMR) machinery. MSI is significantly associated 
with the human heredity nonpolyposis colorectal cancer (HNPCC) syndrome (Fearon 2011). The 
gene most commonly inactivated in MSI+ cancers is Mlh1, although other MMR proteins including 
MSH2, PMS1, and PMS2 account for a significant subset of gene mutations (Vilar and Gruber 
2010). The incidence of MSI is nearly 100% in HNPCC patients, but occurs in only ~15% of 
sporadic CRC (Aaltonen, Peltomäki et al. 1993). 
The remaining 85% of sporadic CRCs are microsatellite stable, but show a high degree 
of chromosomal instability (CIN) (Rajagopalan, Nowak et al. 2003). CIN tumors display increased 
rates of aneuploidy, such as the translocations frequently cited on chromosome 18q, and high 
levels of LOH at tumor suppressor genes (Fearon 2011). The CIN phenotype is considered 
dominant; when CIN cells are fused with non-CIN cells, a CIN phenotype is transferred. When 
two non-CIN cells are fused, the mere presence of 4 copies of each chromosome does not 
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induce CIN, indicating the cancer cells harbor a specific phenotype (Lengauer, Kinzler et al. 
1997). CIN tumors also associate with mutations in the genes encoding spindle-related proteins, 
such as BUB1 and MAD2 (Cahill, Lengauer et al. 1998, Michel, Liberal et al. 2001). However, 
there has been continued speculation that the CIN phenotype is simply an artifact of cancer 
progression, and this argument will likely continue until a molecular mechanism for CIN is found 
(Pino and Chung 2010). 
There are also several human genetic syndromes that predispose to CRC. Familial 
adenomatous polyposis (FAP) patients have germ-line APC mutations, leaving them with only 
one functional copy of this crucial tumor suppressor protein (Fearon 2011). Thus, the likelihood of 
loss of heterozygosity at the APC locus is dramatically increased in FAP patients, and nearly 
100% of cases develop CRC by 36 years of age (Galiatsatos and Foulkes 2006). Typical 
treatment for FAP involves resection of the colon in early adulthood to prevent development of 
metastatic CRC (Lynch and de la Chapelle 2003). Although FAP accounts for only 0.5% of CRC 
cases (Fearon 2011), its genetic basis has made it attractive for use in model organisms. The 
ApcMin/+ mouse model is based on the human FAP syndrome, and is the main model for studies of 
CRC development and progression (Su, Kinzler et al. 1992). Tumors in Apcmin/+ mice are Apc-
negative, demonstrating that loss of heterozygosity (LOH) is required for tumor development 
(Luongo, Moser et al. 1994). Interestingly, ApcMin/+ mice form tumors predominantly in the small 
intestine, as opposed to human FAP, which develops adenomas in the colon (Su, Kinzler et al. 
1992). The cause for this different anatomical site is not well understood, although it has been 
noted that several markers of human CRC, such as the CBC stem cell marker Olfm4, are not 
expressed in the murine colonic epithelium (van der Flier, Haegebarth et al. 2009). Nevertheless, 
ApcMin/+ mice have proven to be a useful tool in understanding both intestinal and colorectal 
tumorigenesis.  
The epigenetic contribution to CRC has been studied extensively over the past thirty 
years, but there is still much we do not understand about its role in carcinogenesis. The majority 
of these studies focused on the function of DNA methylation, because colorectal cancers 
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generally display genome-wide hypomethylation that occurs early in the adenoma-carcinoma 
progression sequence (Goelz, Vogelstein et al. 1985, Feinberg, Gehrke et al. 1988). Below, we 
outline the proposed function of altered epigenetics in human CRC, and the information we have 
gleaned from studies of DNA methyltransferase mutations in mouse models of intestinal and 
colorectal cancer.  
 
DNA methylation patterns in human colorectal cancer 
 The precise function of hypomethylation in human CRC progression is not well 
understood. The earliest epigenetic profiling of cancer cells noted genome-wide hypomethylation 
in malignant human colorectal tumors (Feinberg and Vogelstein 1983, Gama-Sosa, Slagel et al. 
1983). In later studies, it was discovered that even benign polyps and precancerous adenomas 
were substantially demethylated, with a reduction of 8-10% compared to histologically normal 
adjacent tissue (Goelz, Vogelstein et al. 1985, Feinberg, Gehrke et al. 1988). These results were 
striking, and implicated a role for DNA methylation in colorectal tumorigenesis. Global genomic 
hypomethylation may cause activation of proliferation-associated genes, and leads to increased 
mutation rates based on in vitro data (Chen, Pettersson et al. 1998). Analyses of human CRC cell 
lines indicates that hypomethylation causes expression of previously silenced genes (Nakamura 
and Takenaga 1998), and correlated with increased genomic instability (Lengauer, Kinzler et al. 
1997). Ablation of DNMT1 in a human CRC cell line caused hypomethylation, DNA replication 
defects, cell cycle arrest, and apoptosis (Chen, Hevi et al. 2007).  
 Notably, in CRC tumor suppressor genes often display decreased expression, few 
genetic alterations, and increased promoter or CGI methylation. This promoter hypermethylation 
has been studied extensively, and is a defining characteristic of the CpG Island Methylator 
Phenotype, or CIMP (Toyota, Ahuja et al. 1999). CIMP-high (CIMP-H) tumors display increased 
DNA methylation at CGIs of tumor suppressors including CDKN2A (p16), THBS1, and Mlh1. 
CIMP-H tumors account for nearly all CRCs containing oncogenic BRAF/MAPK-pathway 
mutations (Weisenberger, Siegmund et al. 2006), and is also common among tumors displaying 
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MSI (Issa 2004). In sporadic MSI+ tumors, DNA mismatch repair (MMR) genes are often 
inactivated via promoter hyper-methylation. The association of MSI with CGI hypermethylation at 
multiple tumor suppressor genes strongly implicates CIMP as the underlying cause of genomic 
instability in MSI (Weisenberger, Siegmund et al. 2006). MSI also correlates with loss of genomic 
imprinting (Cui, Horon et al. 1998), and mutations at the SWI/SNF chromatin-remodeling gene 
ARID1A (Jones, Li et al. 2012). 
 With the advent of next-generation sequencing, there have been multiple studies aiming 
to profile the epigenome of human CRC (Irizarry, Ladd-Acosta et al. 2009, Berman, 
Weisenberger et al. 2012, Network 2012). The Cancer Genome Atlas Network published an 
extensive study profiling DNA methylation and RNA expression from hyper-mutated versus non-
hypermutated categories of tumors (2012). They observed that non-hypermutated tumors, 
regardless of CIMP status, displayed similar DNA methylation and gene expression patterns. In 
accordance with previous studies, they found that hyper-mutated cancers were enriched for 
hypermethylation and CIMP-H status, as well as BRAF mutations (Network 2012).  
 The mechanism underlying CIMP is not known. Several studies have reported that DNMT 
overexpression underlies this phenotype (Nosho, Shima et al. 2009), but numerous reports have 
refuted this mechanism (Eads, Danenberg et al. 1999). One study suggests that aberrant DNA 
methylation in CRC may involve the repressive Polycomb complex. Widschwendter et al. 
reported a 12-fold enrichment for Polycomb target sequences among hypermethylated regions in 
CRC (2007). Polycomb repressive complexes interact with DNMTs in human cell lines, and the 
EZH2 subunit of Polycomb is required to recruit DNMTs to H3K27-methylated CpGs (Viré, 
Brenner et al. 2006). Thus, in cancer, EZH2 activity may attract DNA methylation to permanently 
silence target genes, predisposing to cancer development. 
 Irizarry and colleagues performed genome-wide bisulfite sequencing in human colorectal 
tumors to assess exactly where hypermethylation occurs relative to CGIs and transcription start 
sites (2009). Interestingly, they found that hypermethylation in CRCs is enriched at CGI shores, 
defined as the regions 2KB upstream and downstream of a respective CGI. The CGI enrichment 
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data for CRCs are similar to the distribution they found for tissue-specific differentially methylated 
regions (DMRs) in normal tissues (Irizarry, Ladd-Acosta et al. 2009). Furthermore, they found 
nearly equal amount of hypo- and hyper-methylated CGI shores in CRC compared to normal 
colon, suggesting that both types of methylation aberrations are involved in cancer formation. 
Many of these so-called cancer DMRs were enriched for tissue-specific DMRs, such as spleen, 
liver and brain, and gene ontology of the cancer-specific DMRs identified gene categories 
involved in pluripotency and development (Irizarry, Ladd-Acosta et al. 2009). Thus, many of the 
same pathways and tissues involved in development are altered in human CRC. This idea forms 
the basis for the epigenetic progenitor model of cancer, in which aberrant activity of differentiation 
pathways causes cancer (Jones and Baylin 2007). 
 
DNA methylation in CRC: Lessons from Mouse models  
 The ApcMin/+ model, based on human FAP, forms the basis for in vivo studies of intestinal 
carcinogenesis. The ApcMin/+ mice develop multiple tumors throughout the intestinal epithelium, 
with microadenomas visible by 3 months of age (Moser, Pitot et al. 1990, Su, Kinzler et al. 1992, 
Laird, Jackson-Grusby et al. 1995). The earliest reports of the effects of DNA hypomethylation on 
tumorigenesis in ApcMin/+ mice utilized a combination of Dnmt1 hypomorphic alleles and the 
pharmacological Dnmt inhibitor 5-aza-deoxycytidine (5-aza). Laird and colleagues produced 
ApcMin/+;Dnmt1S/+ hypomorphic mice, and treated them with 5-aza from one week of age to induce 
DNA hypomethylation. At 100 days, they observed that the ApcMin/+;Dnmt1S/+ 5-aza treated mice 
had only two intestinal polyps, compared to 113 in the ApcMin/+ no 5-aza control. They concluded 
that DNA hypomethylation is not a causative factor in intestinal tumor development, and that DNA 
methylation is required for intestinal carcinogenesis. 
 Further studies enhanced this hypothesis, using varying Dnmt1 hypomorphic alleles on 
the ApcMin/+ background. Cormier and Dove (2000) used ApcMin/+;Dnmt1N/+ mice to show that 
Dnmt1 regulates both intestinal tumor incidence and size, and noted that tumor suppression in 
this model was not dependent on p53. Eads and colleagues built on these data by constructing a 
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ApcMin/+;Dnmt1N/R mouse line, which displayed severe hypomethylation and no polyp formation 
(2002). They also found that these mice display reduced CGI hypermethylation at tumor 
suppressor genes, and conclude that CGI hypermethylation is required for intestinal tumor 
development (Eads, Nickel et al. 2002). 
 The most recent report more closely analyzes the varying stages of colonic tumor 
development in the absence of Dnmt1 (Yamada, Jackson-Grusby et al. 2005). ApcMin/+;Dnmt1chip/c  
mice exhibit reduced DNA methylation and colon macroadenoma formation, as expected. 
Interestingly, ApcMin/+;Dnmt1chip/c  mice displayed increased numbers of colonic microadenomas, 
suggesting that Dnmt1 is not required to initiate tumors, but is required for their sustained growth. 
It should be noted that ApcMin/+ mice typically do not develop colonic tumors; unlike human FAP, 
ApcMin/+ mice develop primarily intestinal tumors. Yamada et al.’s ApcMin/+ colon controls only 
contain ~1 tumor per mouse, as opposed to the 100+ tumors an ApcMin/+ intestine would produce 
(Yamada, Jackson-Grusby et al. 2005). As a result, it is difficult to draw precise conclusions from 
this model.  
 Due to the impact of the CIMP phenotype in human CRC research, the function of de 
novo Dnmts in mouse tumor development has also been a significant area of research. Inducible 
overexpression of Dnmt3a had no effect on colon tumorigenesis on the ApcMin/+ background 
(Linhart, Lin et al. 2007). In the same study, inducible overexpression of Dnmt3b increased the 
number of colonic and intestinal macroscopic adenomas. Linhart and colleagues also report that 
Dnmt3b overexpression increased de novo methylation at Sfrp2, Sfrp4, and Sfrp5, which are 
endogenous suppressors of Wnt signaling (2007). Sfrp genes are common targets of promoter 
hypermethylation in human CRCs (Suzuki, Watkins et al. 2004). In related studies in human 
colorectal cancer cell lines, demethylation of Sfrp gene promoters reactivated the associated 
genes, halting cell proliferation and inducing apoptosis (Suzuki, Watkins et al. 2004).  
 Additionally, Dnmt3b overexpression in ApcMin/+ mice causes hypermethylation of similar 
gene sets in both colonic tumors and adjacent normal epithelium. Dnmt3b had no effect on the 
typical CIMP tumor suppressors, such as Mlh1 or Mgmt, implying that Dnmt3b targets specific 
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genes for hypermethylation (Linhart, Lin et al. 2007). Overall, these results suggest that Dnmt3b 
may promote the formation of colorectal cancers, and has a transformative effect on normal 
colonic epithelium. 
 The same group also published a study assessing the requirement for Dnmt3b in ApcMin/+ 
tumor development. They used the Cre-loxP recombination system to produce a colon-specific 
Dnmt3b deletion on the ApcMin/+ background. Lin and colleagues did not report any variation in 
normal wild-type mucosa in the absence of Dnmt3b (2006). In ApcMin/+ mice, loss of Dnmt3b led to 
a significant decrease in the number of macroscopic colonic tumors, but did not affect 
microadenoma initiation. The Dnmt3b deletion was fairly mosaic; only about half of 
microadenomas demonstrated loss of Dnmt3b protein. All mature tumors, however, contained 
patches of Dnmt3b+ cells, indicating an active selection against Dnmt3b-null microadenomas in 
tumor development (Lin, Yamada et al. 2006). These results suggest that Dnmt3b is crucial for 
progression to adenoma, but may not be essential to maintain a fully formed tumor.  
 Based on the above studies, one could conclude that DNA hypomethylation is 
unimportant for tumor development. However, there are several problems with these studies that 
remain to be addressed in the future. The above experimental models employed hypomorphic 
Dnmt1 alleles, which caused hypomethylation in all tissues from early development onward. As a 
result, the observed phenotypes may be due to developmental defects or intestine-independent 
effects of hypomethylation. For instance, mesenchyme-specific transcription factors, such as 
Foxl1, are important modifiers of the ApcMin/+ phenotypes (Perreault, Sackett et al. 2005), and 
may be affected in Dnmt1-hypmorphic mice. Dnmt1 is also required for embryonic development 
(Li, Bestor et al. 1992), and may play an important role in organogenesis as well (Georgia, Kanji 
et al. 2013). Although the role of Dnmt1 in the developing intestinal epithelium is unknown, in the 
mature epithelium Dnmt1 supports differentiation processes and restricts the proliferative stem 
cell zone (Sheaffer, Kim et al. 2014). Indeed, loss of Dnmt1 in the adult intestinal epithelium 
causes a two-fold expansion of the crypt compartment (Sheaffer, Kim et al. 2014), suggesting 
that methylation plays essential roles in regulating proliferative processes. Thus, it would be 
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valuable to reassess the role of Dnmt1 in the ApcMin/+ colorectal cancer model using epithelial 
specific and/or inducible Cre-loxP mouse models. In this work, I describe the function of Dnmt1 
during perinatal intestinal development and ApcMin/+ intestinal cancer progression.  
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Figure 1.1. The mammalian intestinal epithelium. 
Longitudinal cross section of the adult intestinal epithelium. The intestinal epithelium is a single 
cell layer lining the lumen of the intestine, and is structured into proliferative crypts and 
differentiated villi. Crypts contain both proliferative CBC stem cells and quiescent +4 stem cells. 
These stem cells give rise to rapidly dividing transit-amplifying cells, which begin differentiation as 
they migrate out of the crypt. Secretory progenitors differentiated into goblet cells, 
enteroendocrine cells, Paneth cells. Enterocyte progenitors develop into absorptive enterocytes, 
which comprise ~90% of the epithelium.   
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Figure 1.2. Opposing roles for epigenetic modifications in the intestinal epithelium. 
(A,B) Cdx2 maintains the open chromatin state at enhancers during intestinal differentiation. In 
proliferating cells Cdx2 is not bound at differentiation-enhancers, and these regulatory regions 
display reduced H3K4me2 (A). As a result, these genes are not highly expressed. In 
differentiating cells, Cdx2 and Hnf4a bind at enhancer regions marked by increased H3K4me2, 
which activates expression of enterocyte-lineage genes (B). Cdx2 supports H3K4me2 di-
methylation, presumably by MLL methyltransferase complex activity. Loss of Cdx2 binding in 
these regions leads to reduced H3K4me2 in differentiated villus cells (Verzi, Shin et al. 
2013)(Verzi, Shin et al. 2013)(Verzi, Shin et al. 2013)(Verzi, Shin et al. 2013)(Verzi, Shin et al. 
2013)(Verzi, Shin et al. 2013).  
(C,D) DNA methylation at enhancers upstream of proliferation and/or stem cell genes regulates 
cell division in crypts. In dividing intestinal cells, enhancers are unmethylated (C), allowing Cdx2 
to bind and activate progenitor gene expression. In differentiated cells, enhancers associated with 
stem cell genes are methylated (D). DNA methylation restricts access by transcription factors, 
and genes are silenced. 
 (A,B) adapted from Verzi et al. 2010. (C,D) adapted from Sheaffer et al. 2014.  
  
	   	    35	  
 
	  
Chapter 2 
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General Protocols 
Animals and genotype analysis Dnmt1loxP/loxP and Dnmt3bloxP/loxP mice were kindly provided by 
Rudolf Jaenisch (Jackson-Grusby, Beard et al. 2001, Lin, Yamada et al. 2006), and 
VillinCreERT2 mice were received from Sylvia Robine (el Marjou, Janssen et al. 2004). VillinCre 
(Madison, Dunbar et al. 2002) and ApcMin/+ mice (Moser, Pitot et al. 1990, Su, Kinzler et al. 1992) 
were obtained from The Jackson Laboratory. Genotyping was performed by PCR analysis. For 
VillinCreERT2-mediated deletion experiments, Cre-recombination was induced by three daily 
intraperitoneal injections of 1.6 mg tamoxifen (Sigma) in an ethanol/sunflower oil mixture. 
Littermate controls without the VillinCreERT2 transgene also received tamoxifen treatment. For 2-
hour EdU analysis, I administered EdU by intraperitoneal injection 2 hours prior to dissection. I 
administered 0.1 mg EdU (Invitrogen) for postnatal day 0 (P0) mice, and 1 mg EdU for 3-month 
old adult mice. All procedures involving mice were conducted in accordance with approved 
Institutional Animal Care and Use Committee protocols. 
Histology, immunohistochemistry, and immunofluorescence Intestines were fixed O/N in 4% 
paraformaldehyde and embedded in paraffin. Hematoxylin and eosin (H&E) staining were used to 
assess global morphology of intestinal epithelial specimens. For all antibody staining, slides were 
dewaxed and antigen retrieval was performed using the 2100 Antigen-Retriever and R-Buffer A 
(Electron Microscopy Sciences). Standard immunohistochemistry staining was performed for 
Dnmt1 (Santa Cruz 20701, 1:200), Ki67 (BD Pharmingen 550609, 1:500), and β-catenin (BD 
Transduction 610153, 1:200) using the ABC detection system (Vector Laboratories). Briefly, 
following antigen retrieval all slides were blocked with 3% H2O2, avidin, and biotin (Vector 
Laboratories). Additionally, for staining of Dnmt1 slides were blocked for 30 minutes with CAS 
Block (Invitrogen), and for staining of Ki67 and β-catenin slides were blocked for 15 minutes with 
StartingBlock T20 blocking buffer (Thermo Scientific). Sections were incubated with respective 
primary antibody at 4°C overnight, with the exception of Dnmt1, which was diluted in Antibody 
Diluent Reagent Solution (Invitrogen). The next day, slides were incubated with biotinylated 
secondary antibody (Vector Laboratories) followed by treatment with ABC reagent, and 
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developed with DAB (Vector Laboratories). P21 immunohistochemistry (BD Pharmingen 556430, 
1:50) was performed as described previously (van de Wetering, Sancho et al. 2002). Standard 
immunofluorescence procedures were performed with the following antibodies: Chromogranin A 
(Immunostar 20085, 1:200), Ki67 (BD Pharmingen 550609, 1:500), Dnmt3a (Santa Cruz 20703, 
1:500), Dnmt3b (Imgenex 184A, 1:500), E-cadherin (BD Transduction Lab 610181, 1:500), 
Epcam (Abcam 71916, 1:500), Lysozyme (Dako A0099, 1:3,000), Mucin2 (Santa Cruz 15334, 
1:50), γH2AX (Cell Signaling 2577L, 1:250), and phosphorylated histone H3 (Cell Signaling 3377, 
1:500). For E-cadherin, γH2AX, and PH3 staining, tissues were blocked for 15 minutes with CAS 
Block (Invitrogen). For staining of Ki67, Chromogranin A, Lysozyme, Mucin2, Dnmt3a, and 
Dnmt3b, tissues were blocked for 2 hours at room temperature with 5% normal donkey serum 
(EMD Millipore) in 1% BSA in PBS. For Epcam and Ki67, sections were blocked for 15 minutes 
with StartingBlock T20 blocking buffer (Thermo Scientific). All tissues were incubated with 
respective primary antibody overnight at 4°C. The following day, slides were incubated with 
immunofluorescent secondary antibodies (The Jackson Laboratory), counterstained with DAPI, 
and mounted with fluorescence mounting medium. Co-staining was accomplished by sequential 
immunohistochemistry and immunofluorescent antibody staining. Alkaline phosphatase staining 
was performed using NBT and BCIP (Boehringer). Immunofluorescent TUNEL staining was 
performed using TUNEL Label and Enzyme (Roche) and AlexaFluor 555-aha-dUTP (Life 
Technologies). For cell replication analysis, we used the Click-iT EdU Alexa Fluor 555 Imaging Kit 
(Invitrogen). All microscopy was performed on a Nikon Eclipse 80i. 
mRNA expression analysis Small intestines and macroscopic tumors were isolated and 
immediately frozen in Trizol (Invitrogen). RNA was extracted using the Trizol RNA isolation 
protocol (Invitrogen), followed by RNA cleanup using the RNeasy Mini Kit (Qiagen). mRNA 
expression was measured using quantitative RT-PCR, as described previously (Gupta, Gao et al. 
2007). The SYBR green qPCR master mix (Agilent) was used in all qPCR reactions, and the fold 
change was calculated relative to the geometric mean of Tbp and β-Actin, using the ΔCT method. 
The method of normalizing to the geometric mean of a set of reference genes has been 
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described previously (Vandesompele, De Preter et al. 2002). Primer sets can be found in Table 
2.1. 
  
Protocols specific for Chapter 3: Dnmt1 is essential to maintain progenitors in the 
perinatal intestinal epithelium. 
Cell counting in the Dnmt1-deficient neonatal intestine For villi quantification, H&E sections of 
tissue were scanned at 10X using Metamorph imaging software (Molecular Devices). Per 
biological replicate, villi were counted for ≥20 mm tissue, measured using ImageJ (Schneider, 
Rasband et al. 2012). For TUNEL and γH2AX quantification, 500 intervillus cells were counted at 
20X for each biological replicate. Intervillus cells were defined as 20 µm from the base of the 
intestinal epithelium. 
EdU quantification in the adult and neonatal intestinal epithelium For EdU quantification, I 
harvested jejunum from five Dnmt1loxP/loxP 3-month old adult mice, and three litters of Dnmt1loxP/loxP 
P0 mice (4 mice per litter). I defined the crypt-villus subunit as the epithelium lying between the 
peaks of two adjacent villi that share the same crypt. I counted the total number of EdU+ nuclei 
per crypt or intervillus region, and divided this number by the total number of nuclei per crypt 
villus subunit. Per adult sample, I counted ~8 crypt-villus subunits. Per P0 sample, I counted ~25 
crypt-intervillus subunits. 
Laser capture microdissection, RNA-Seq, and mRNA expression analysis Laser capture 
microdissection (LCM) was performed from unstained sections of paraffin-embedded, methacarn-
fixed proximal jejunum for 3 controls and 2 mutants, as described previously (Miyoshi, Ajima et al. 
2012). For laser-capture microdissection (LCM), proximal jejunum was collected from 
Dnmt1loxP/loxP; VillinCre neonatal litters. Tissue was fixed for one hour in cold methacarn solution 
(60% methanol, 30% chloroform, 10% glacial acetic acid), washed 3 times in cold 70% ethanol, 
and submitted for paraffin embedding and sectioning. Serial sections were cut for mutants 
(Dnmt1loxP/loxP; VillinCre, n=2) and controls (Dnmt1loxP/+, n=3). Odd numbered sections were 
mounted onto charged glass slides, and were used for Ki67 IF staining as described above. Ki67 
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stained sections were scanned using a 10X objective and Metamorph imaging software; scans 
served as the map for LCM on unstained sections. Even numbered sections were mounted onto 
non-charged glass slides for use in LCM.  
The PixCell II LCM system (Arcturus, Applied Biosystems; 7.5-µm diameter laser spot) 
was used to capture Ki67- intervillus cells from mutants (n=2) and Ki67+ intervillus cells from 
controls (n=3). Captured cells were collected onto CapSure HS LCM caps (Applied Biosystems), 
and total cellular RNA was extracted using the PicoPure RNA isolation kit (Applied Biosystems). 
RNA concentration and quality was assessed on an Agilent 2100 Bioanalyzer (Agilent 
Technologies). Total RNA isolated by LCM (2.3 ng to 33.3 ng per sample) was amplified using 
the Ovation RNA-Seq System V2 (NuGEN). 300 ng of each sonicated cDNA sample was used for 
RNA-Seq library preparation. cDNA sequencing libraries were completed using NEBNext Ultra 
RNA Library Prep Kit for Illumina (New England Biolabs), Illumina multiplexing adaptors, and the 
NEBNext ChIP-Seq DNA Sample Prep Reagent Set 1 Kit (New England Biolabs). Single-read 
sequencing was performed on the Illumina HiSeq 2000 (100 bp reads).  
Reads (a minimum of 25 million per sample, ~80% unique mapped reads) were aligned 
to the mouse reference genome (NCBI build 37, mm9) using TopHat (Trapnell, Roberts et al. 
2012). TopHat was run with the University of California at Santa Cruz refFlat annotation file (GTF 
format) and the “–no-novel-juncs” option to map reads only in the reference annotation. Cutdiff 
was used to calculate gene expression levels (Trapnell, Roberts et al. 2012). Messenger RNA 
levels were expressed in reads per kilobase of transcript per million mapped reads (RPKM). 
Gene Ontology analysis was performed using DAVID (Ashburner, Ball et al. 2000). Cutdiff results 
were filtered by FDR<0.1, and separated into two categories, upregulated genes and 
downregulated genes. DAVID functional annotation analysis was performed separately for each 
gene set. 
RNA isolation and qRT-PCR to confirm RNA-Seq For confirmation of RNA-Seq results, 
proximal jejunal RNA samples were collected by Laser Capture Microdissection using a Leica 
LMD7000 Laser Microdissection microscope, as described above. Approximately 10,000 cells 
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were collected per sample. RNA was isolated and cDNA amplified using the protocols described 
for the RNA-Seq libraries. The SYBR green qPCR master mix (Agilent) was used in all qPCR 
reactions, and the fold change was calculated relative to the geometric mean of five reference 
genes: Tbp, b-Actin, Rplp0, Polr2b, and B2m using the ΔCT method. Primer sets can be found in 
Table 2.1. 
Organoid culture For neonatal Dnmt1loxP/loxP (n=3) and Dnmt1loxP/loxP; VillinCre (n=2) organoid 
culture, duodenum and jejunum were opened longitudinally in cold PBS, cut into 10mm pieces, 
and incubated in EDTA. Vigorous pipetting released the epithelia from the tissue, and cells were 
embedded in Matrigel (BD Biosciences) for cell culture, as described previously (Sato, Vries et al. 
2009). All organoids were grown at 37°C, 5% CO2. Cell media (Advanced DMEM/F12, Invitrogen) 
was supplemented with GlutaMax (Invitrogen), Hepes (Invitrogen), Pen/Strep (Invitrogen), N2 
(Invitrogen), B27 (Invitrogen), and N-Acetylcysteine (Sigma). The following growth factors were 
added to media: mEGF (Invitrogen), mNoggin (Peprotech), hR-Spondin (Peprotech). For the first 
two days of neonatal organoid growth, cultures were also supplemented with Y-27632 (Sigma) 
and CHIR-99021 (Biovision). The medium was changed every other day.   
Crypts were isolated from jejunum of 3-month-old Dnmt1loxP/loxP; VillinCreERT2 (n=4) and 
Dnmt1loxP/loxP (n=2) mice for organoid culture as described previously (Sato, Vries et al. 2009). 
The following growth factors were added to media: mEGF (Invitrogen), mNoggin (Peprotech), hR-
Spondin (Peprotech), and CHIR-99021 (Biovision). The medium was changed every other day. 
For VillinCreERT2 induction, 4-hydroxytamoxifen (Sigma H7904) was added to organoid media at 
a final concentration of 100nm (Sato, Vries et al. 2009). After 48 hours, the 4OHT medium was 
removed and fresh medium was added to each well. The 100nm concentration was not 
detrimental to Dnmt1loxP/loxP control organoids at either time point (Fig. S10 and S11). 
 2 hours prior to organoid harvest, EdU (Invitrogen) was added to each well (10mm). 
Organoids were harvested using cold PBS, and were fixed in 4% PFA for 1 hour at 4°C. Organoid 
pellets were suspended in agarose, embedded in paraffin, and sectioned for 
immunohistochemistry analysis.  
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Laser capture microdissection and targeted bisulfite sequencing DNA was isolated from 
paraffin-embedded tissue sections using a Leica LMD7000 Laser Microdissection microscope 
and the Arcturus PicoPure DNA isolation kit (Applied Biosystems). LCM-isolated DNA was 
bisulfite-converted and purified using the Epitect Bisulfite Kit (Qiagen). Template DNA was 
amplified using the KAPA HiFi HotStart Uracil+ ReadyMix PCR Kit (Kapa Biosystems). The 
LINE1 and H19 PCR assays were described previously (Lane, Dean et al. 2003, Samuel, Suzuki 
et al. 2009). Additional primer sets were designed using PyroMark software (Qiagen) and are 
listed in Table 2.2. Adult Dnmt1loxP/loxP;VillinCreERT2 mutant and Dnmt1loxP/loxP control crypt DNA 
were kindly provided by K.L.Sheaffer (Sheaffer, Kim et al. 2014).  
Sequencing libraries were made using the Ovation SP Ultralow Library system and 
Mondrian SP+ Workstation (NuGEN). Libraries were pooled at 8 nM, and 150bp paired end 
sequencing was performed on the Illumina MiSeq (MiSeq v2 Reagent Kit, 300 cycles PE). 
Converted sequence was aligned to the mouse genome (NCBI build 37, mm9) using BS Seeker 
(Chen, Cokus et al. 2010). 
Data Access All RNA sequencing data generated in this study have been deposited in the NCBI 
Gene Expression Omnibus (Edgar, Domrachev et al. 2002) under accession number GSE67363.  
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Protocols specific for Chapter 4: Dnmt1 and Dnmt3b are required for genomic stability in 
intestinal epithelial homeostasis. 
Tumor evaluation procedures Macroscopic tumors were counted immediately after tissue 
isolation using a stereoscope. Microadenoma counts were performed on sections stained with 
hematoxilyn and eosin (H&E) for the small intestine and sections stained with β-catenin for the 
colon. Microadenoma size was calculated by measuring the width of neoplastic lesions on H&E 
stained small intestine sections using ImageJ (Schneider, Rasband et al. 2012). Histological 
pathology was performed as described previously (Boivin, Washington et al. 2003).  
Loss of heterozygosity at the Apc locus Tumor and non-tumor epithelial cell DNA were 
collected using a Leica LMD7000 Laser Microdissection microscope and the Arcturus PicoPure 
DNA isolation kit (Applied Biosystems). LOH was performed as done previously (Luongo, Moser 
et al. 1994). 
Phosphorylated-H3 cell cycle quantification ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mutants and 
sibling ApcMin/+;Dnmt1loxP/loxP controls were injected with tamoxifen at 1 month of age. Small 
intestines were collected one month and two months following tamoxifen administration, in 
separate cohorts of mice. Following fixation, tissue sections were co-stained for phosphorylated 
histone H3 (PH3) to identify cells in M-phase, and β-catenin to identify hyper-proliferative 
neoplastic epithelium. I counted the number of PH3+ nuclei, and divided it by the total number of 
nuclei in the respective region. This calculation was performed for neoplastic intestinal epithelium 
at both time points, for controls and mutants.  
Laser capture microdissection Tumor and non-tumor epithelial cell DNA was collected using a 
Leica LMD7000 Laser Microdissection microscope and the Arcturus PicoPure DNA isolation kit 
(Applied Biosystems). 
Targeted bisulfite sequencing 100 ng of mouse genomic DNA was bisulfite converted using the 
Epitect bisulfite kit (Qiagen). Template DNA was amplified using the KAPA HiFi HotStart Uracil+ 
ReadyMix PCR Kit (Kapa Biosystems) with primers directed to the H19 ICR and LINE1 region 
and modified with partial Illumina adapter overhangs (PCR#1 F/R). Samples were barcoded by 
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incorporation of a unique DNA sequencing barcode in a subsequent round of PCR amplification 
(PCR#2 F/R). Samples were pooled at 2nM, and 150bp paired end sequencing was performed 
on the Illumina MiSeq (MiSeq v2 Reagent Kit, 300 cycles PE). Converted sequences were 
aligned to the mouse genome (NCBI build 37, mm9) using BS Seeker (Chen, Cokus et al. 2010). 
Primer sequences can be found in Table 2.3. 
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Chapter 3 
 
Dnmt1 is essential to maintain progenitors in the perinatal 
intestinal epithelium 
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Abstract 
The DNA methyltransferase Dnmt1 maintains DNA methylation patterns and genomic 
stability in several in vitro cell systems. Ablation of Dnmt1 in mouse embryos causes death at the 
post-gastrulation stage; however, the functions of Dnmt1 and DNA methylation in organogenesis 
remain unclear. Here, I report that Dnmt1 is crucial during perinatal intestinal development. Loss 
of Dnmt1 in intervillus progenitor cells causes global hypomethylation, DNA damage, premature 
differentiation, and apoptosis, and consequently, loss of nascent villi. I further confirm the crucial 
role for Dnmt1 during crypt development using the in vitro organoid culture system, and illustrate 
a clear differential requirement for Dnmt1 in immature versus mature organoids. These results 
demonstrate an essential role for Dnmt1 in maintaining genomic stability during intestinal 
development and the establishment of intestinal crypts. 
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Introduction 
 
DNA methyltransferase 1 (Dnmt1) maintains DNA methylation following DNA replication, 
but little is known about its requirement for organ development. Previous studies of mice with 
global deletion of Dnmt1 failed to define the contribution of maintenance methylation during 
organogenesis, because Dnmt1 null mice die shortly after gastrulation, at approximately 
embryonic day 9.5 (E9.5) (Li, Bestor et al. 1992). With the advent of Cre-loxP recombination 
technology and tissue specific gene ablation, the role of Dnmt1 in organ development can now be 
addressed. For example, Dnmt1 has been ablated during neuronal development and shown to be 
essential for the survival of fetal mitotic neuroblasts (Fan, Beard et al. 2001). Dnmt1-ablated 
neuroblasts are 95% hypomethylated, and mice die just after birth due to respiratory defects, 
demonstrating a clear role for Dnmt1 in organ development and cellular differentiation (Fan, 
Beard et al. 2001). In the fetal pancreas, deletion of Dnmt1 causes a decrease in differentiated 
pancreatic cells with a concomitant increase in p53 levels, cell cycle arrest, and progenitor cell 
apoptosis. However, this phenotype is dependent on direct binding of the Dnmt1 protein to the 
p53 (Trp53) locus, and was suggested to be caused by a DNA-methylation independent effect of 
Dnmt1 (Georgia, Kanji et al. 2013). Thus, it remains unclear whether and how Dnmt1 and 
maintenance DNA methylation control different organs during development.  
The intestinal epithelium is an especially tractable system for the study of stem cell 
maintenance and cellular differentiation. Important differences between the neonatal and adult 
intestinal epithelium led us to investigate the role for Dnmt1 during fetal gut development. 
Previous work had shown that Dnmt1 controls cellular differentiation in the mature intestinal 
epithelium, but is dispensable for organ maintenance and organismal survival in adult mice 
(Sheaffer, Kim et al. 2014). However, the intestinal stem cell niche does not develop until 
approximately one week after birth in mice. During fetal gut development, proliferative progenitor 
cells become progressively restricted to the intervillus epithelium. Following birth, the proliferative 
intervillus regions invaginate into the underlying mesenchyme to form intestinal crypts. As a 
result, there is no defined stem cell population in the late fetal and perinatal intestinal epithelium. 
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Furthermore, the mitotic index of intestinal epithelial progenitors is highest during the late 
embryonic and postnatal period, during which time the rate of cell production must dramatically 
exceed the rate of cell extrusion at the villus tip to allow for rapid villus growth (Al-Nafussi and 
Wright 1982, Itzkovitz, Blat et al. 2012). This higher rate of cell turnover may indicate a distinct 
requirement for maintenance DNA methylation, as any delay in cell division would be expected to 
impair organ development.  
Prior studies have failed to provide a clear explanation as to why loss of DNA methylation 
during organ development, such as in the brain, causes cell death (Fan, Beard et al. 2001). 
Rescue of the cell death phenotype in Dnmt1-deficient cultured fibroblasts via inactivation of 
Trp53 strongly suggests that the p53 pathway is partially responsible (Jackson-Grusby, Beard et 
al. 2001). In vitro studies of colorectal cancer (CRC) cell lines demonstrate that loss of DNA 
methylation results in genomic instability, DNA damage, and mitotic arrest (Chen, Hevi et al. 
2007). Indeed, hypomethylation leads to increased mutation rates and reduced genomic stability 
(Chen, Pettersson et al. 1998), and in human CRC patients aberrant DNA methylation correlates 
with microsatellite instability (Ahuja, Mohan et al. 1997). Therefore, I set out to determine if loss of 
Dnmt1 causes genomic instability and intestinal development failure in the developing gut. 
Using cell type-specific gene ablation, I discover that Dnmt1 is essential for the 
maintenance of epithelial proliferation and nascent crypt development in the perinatal period. 
Without maintenance DNA methylation, the rapidly growing epithelium displays increased double-
strand breaks, activation of the DNA damage response, and loss of progenitor cells due to both 
premature differentiation and apoptosis. I validate these results utilizing in vitro organoid cultures, 
demonstrating that Dnmt1 is required to establish organoids from the perinatal intestinal 
epithelium, but is not essential for the maintenance of mature organoids derived from adult 
intestinal crypts. These data provide novel evidence for the role of DNA methylation in 
maintaining genomic stability during the development of highly proliferative tissues. 
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Results  
 
Dnmt1 is expressed in the proliferative zone of the embryonic and adult intestinal 
epithelium 
To begin my study of the requirement for Dnmt1 in intestinal epithelial development, I first 
characterized the localization of Dnmt1 protein at different fetal and postnatal stages in the 
mouse. At E16.5, E18.5, and on postnatal day 0 (P0), Dnmt1 protein was restricted to the 
proliferative intervillus regions, while in the adult intestinal epithelium, Dnmt1 was localized to the 
proliferative crypt zone, as previously reported (Figure 3.1) (Sheaffer, Kim et al. 2014). 
Furthermore, prior RNA-Seq analysis of isolated cell populations from the adult intestinal 
epithelium confirms that Lgr5+ crypt-based columnar intestinal stem cells (ISCs) express Dnmt1, 
while differentiated villus cells contain little to no Dnmt1 mRNA (Sheaffer, Kim et al. 2014).  
 
Dnmt1 ablation causes decreased proliferation and genome hypomethylation in the 
perinatal intestinal epithelium 
To investigate the function of Dnmt1 during murine gut development, I employed Cre-
loxP recombination technology to specifically ablate Dnmt1 in the intestinal epithelium. The 
VillinCre transgene has been shown to cause activation of a Cre-dependent lacZ reporter as early 
as E12.5 (Madison, Dunbar et al. 2002), but analysis of late gestation Dnmt1loxP/loxP;VillinCre 
E18.5 embryos revealed highly mosaic ablation of Dnmt1 (Figure 3.2 A-C), and no phenotypic 
effects were observed at this stage (data not shown). The mosaicism can be explained by the fact 
that the efficacy of Cre-mediated gene ablation varies depending on the design of the loxP-
flanked target allele and its localization in chromatin (Baubonis and Sauer 1993, Long and Rossi 
2009). Because Dnmt1loxP/loxP;VillinCre mutants were born at the expected Mendelian ratios, I set 
out to determine the potential requirement for Dnmt1 in the perinatal period.   
The majority of Dnmt1loxP/loxP;VillinCre mutant mice died within the first weeks of life, with 
only ~35% surviving to weaning (Figure 3.3 A). The variable expressivity of the mutant phenotype 
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is explained by the mosaicism of gene ablation in Dnmt1loxP/loxP;VillinCre mice. In the first week of 
life, mutant mice often became runted and failed to compete with healthy littermates for maternal 
resources. I thus confined my analyses to postnatal day 0 (P0) Dnmt1loxP/loxP;VillinCre mice. 
Staining of mutant P0 intestine revealed that Dnmt1 protein was absent from 40-60% of 
progenitor cells (Figures 3.3 C,E and 3.4 A-C). Quantification of the villi present in the mutant 
neonatal intestinal epithelium showed a 25% decrease in villus number compared to littermate 
controls (Fig. 3.3 B); the length of the villi, largely reflecting areas in which Dnmt1 had not been 
deleted, remained similar across genotypes (data not shown).  
To evaluate the possibility that the de novo DNA methyltransferases Dnmt3a and Dnmt3b 
might compensate for Dnmt1 deficiency during gut development, I determined mRNA expression 
and protein localization of these two enzymes in Dnmt1loxP/loxP;VillinCre neonatal mutants and 
Dnmt1loxP/loxP littermate controls. The Dnmt1-deficient intestine did not display increased mRNA 
expression or altered localization of either de novo methyltransferase (Figure 3.4 D-I). Thus, there 
is no compensatory upregulation of expression of Dnmt3a and 3b in the Dnmt1-deficient gut 
epithelium.  
The intestinal epithelium of surviving adult Dnmt1loxP/loxP;VillinCre mutants was 
predominantly Dnmt1+, indicating that “escaper cells” that avoided Cre-mediated excision had 
repopulated the intestinal epithelium in its entirety (Figure 3.2 D-E). The fact that the epithelium of 
surviving Dnmt1loxP/loxP;VillinCre mice is made up primarily of Cre-escaper cells, despite the fact 
that the Villin promoter is active throughout adulthood, demonstrates that Dnmt1-deficient 
progenitor cells are at a severe disadvantage compared to Dnmt1+, Cre-escaper cells. 
To investigate the possible causes for the observed postnatal lethality in Dnmt1-deficient 
mice, I first assessed epithelial cell proliferation. In control Dnmt1loxP/loxP littermates, all Dnmt1+ 
cells are Ki67+; I defined these proliferative areas in the intervillus regions of the neonatal 
intestine as the progenitor zone (Figures 3.3 C-D and 3.5 A-B). The Dnmt1-ablated epithelium 
displayed a striking reduction in the number of replicating cells as indicated by Ki67 staining, with 
many intervillus regions lacking proliferative cells completely (Figures 3.3 E-F and 3.5 C-D). 
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Regions of the gut that retained Dnmt1 expression due to inefficient Cre-mediated gene ablation 
maintained epithelial proliferation, as expected (Figure 3.3 E-F). Furthermore, co-staining of 
Dnmt1loxP/loxP;VillinCre mutants and littermate controls demonstrated the substantial overlap of 
Dnmt1 and Ki67 protein localization (Figure 3.5). These results suggest that Dnmt1 is necessary 
to maintain the proliferation of epithelial progenitors during early postnatal intestinal development.  
Next, I determined if ablation of Dnmt1 resulted in loss of global DNA methylation in 
progenitor cells. The mosaicism of the Dnmt1 mutants precluded mechanistic analysis in bulk 
tissue extracts. To overcome this limitation, I isolated Dnmt1loxP/loxP;VillinCre mutant and 
Dnmt1loxP/+ control jejunal progenitor cells by laser-capture microdissection (LCM). I stained serial 
sections for Ki67 to identify Dnmt1-ablated and Dnmt1-positive areas corresponding to non-
proliferative and proliferative progenitor zones, respectively, and used the adjacent serial sections 
for LCM. I isolated approximately 10,000 cells per biological replicate for DNA methylation 
analysis (n=4 per group). LINE1 repetitive elements comprise 18% of the mouse genome 
(Waterston, Lindblad-Toh et al. 2002) and are a representative measure of genome-wide DNA 
methylation (Lane, Dean et al. 2003, Yang, Estécio et al. 2004). Bisulfite-sequencing of LINE1 
elements demonstrated global demethylation of the mutant genome, exceeding 50% for several 
CpGs, confirming a dramatic loss of maintenance methylation (Figure 3.3 G). To further probe the 
DNA methylation status of mutant cells, I also bisulfite-sequenced the imprinting control region 
(ICR) of the H19 locus. The H19 ICR is methylated on the paternal allele, meaning that H19 is 
only expressed from the maternally inherited copy (Tremblay, Saam et al. 1995). Targeted 
bisulfite-sequencing demonstrated a consistent reduction of DNA methylation at the H19-ICR 
locus in mutants compared to controls (Figure 3.3 H). These data likely still underestimate the 
degree of methylation loss, as even the most careful LCM resulted in the capture of 10% Dnmt1+ 
cells from mutant tissues, as indicated by my RNA-Seq analysis (see below, Figure 3.6 B). 
Overall, these bisulfite-sequencing results indicate a genome-wide reduction in DNA methylation.  
To determine the changes Dnmt1 ablation causes in gene expression, I isolated 
Dnmt1loxP/loxP;VillinCre mutant and Dnmt1loxP/+ control progenitor cells using infrared (IR) laser 
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capture on the Arcturus PixCell IIe (Figure 3.7 A-B). I isolated approximately 10,000 cells from the 
proximal jejunum of each biological replicate and performed RNA-Seq to investigate the global 
transcriptome of intervillus progenitor cells. By combining the transcriptome data with my 
immunostaining analysis, I was able to correlate gene expression changes with protein 
expression and localization alterations in the Dnmt1-ablated intestinal epithelium.  
I found that Dnmt1 expression was reduced by ~90% in our mutant samples, with the 
remaining Dnmt1 transcripts stemming from contaminating mesenchymal or Cre-escaper cells, as 
indicated by RNA-Seq analysis of Dnmt1 exon 5, which is excised upon Cre-activation (Jackson-
Grusby, Beard et al. 2001) (Figure 3.6 B). By contrast, Dnmt3a and Dnmt3b mRNA levels were 
unaffected, in agreement with my previous observations (Figure 3.6 A). Several imprinted genes, 
including H19, were misregulated in mutant cells (Table 3.1), as expected. DAVID gene ontology 
(GO) analysis (Ashburner, Ball et al. 2000) did not define any specific terms for upregulated 
genes in Dnmt1-mutants, although I found increased expression of several differentiation-related 
genes (Table 3.1 and Figure 3.7 C).  
 
Partial induction of differentiation markers in Dnmt1-deficient progenitor zones 
To test the possibility of premature differentiation of progenitor cells, I combined my RNA-
Seq results with immunostaining for markers of differentiated cells present in the neonatal 
intestine, including enterocytes, Goblet cells, and enteroendocrine cells. These experiments did 
not reveal consistent differences in Goblet cell differentiation and localization compared to age-
matched controls (Figure 3.8 M-P). There were small but statistically significant increases in 
alkaline phosphatase (Alpi) and chromogranin A (Chga) expression in mutant progenitors as 
determined by RNA-Seq (Table 3.1). However, the vast majority of mutant intervillus progenitor 
cells were neither Alpi+ nor Chga+ (Figure 3.8 A-H), suggesting that premature differentiation is 
not the predominant cause of the Dnmt1-mutant phenotype. 
Lysozyme+ Paneth cells do not appear in the normal mouse intestinal epithelium until 
crypt maturation begins at ~P10, and drastically increase in number from P14 to P24 during crypt 
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fission (Bry, Falk et al. 1994). Interestingly, lysozyme (Lyz) expression was markedly increased in 
Dnmt1-ablated intestinal progenitors relative to controls by RNA-Seq, immunofluorescent 
staining, and qRT-PCR (Table 3.1, Figures 3.7 D-E, 3.8 I-L, and 3.6 C, respectively). Further 
analysis of RNA-Seq data showed that mutant progenitors exhibit increased expression of 
several Paneth-cell related genes, including Ang4, Defa20, and Pla2g2a (Table 3.1) (Bevins and 
Salzman 2011). Thus, it appears that a fraction of mutant progenitors halt the cell cycle and 
prematurely differentiate into Paneth cells. However, my staining clearly indicates that only a 
small fraction of mutant progenitors are differentiated (Figures 3.7 D-E and 3.8 I-L), suggesting 
that other pathways, such as apoptosis, may also be activated. It is important to note that the 
perinatal progenitor zone is not a homogeneous stem cell population; indeed, there may be 
subpopulations of different progenitor cell types that are leading to the variable phenotypes we 
observe. 
 
Dnmt1-ablated progenitor cells exhibit altered mRNA expression and DNA methylation of 
cell cycle and DNA damage response genes 
 GO analysis of downregulated genes indicated significant enrichment for the GO terms 
‘cell division’, ‘DNA replication’, and ‘DNA damage response’ (Figure 3.7 C). A subset of these 
misexpressed genes, including Atm, Chek2, p21 (p21CIP1/WAF1 or Cdkn1a), and Mlh1 were 
confirmed in three independent LCM samples by qRT-PCR (Figure 3.6 C-D). These results 
demonstrate that loss of Dnmt1 caused decreased expression of DNA damage response and 
cell- cycle related genes. Dnmt1 is known to play a crucial role in genomic stability, as ablation of 
Dnmt1 in cell lines can result in mitotic defects and G2/M arrest (Chen, Hevi et al. 2007), or DNA 
replication errors and activation of the G1/S checkpoint (Knox, Araujo et al. 2000, Unterberger, 
Andrews et al. 2006). Additionally, loss of Dnmt1 in murine embryonic stem cells increases 
mitotic mutation rates (Chen, Pettersson et al. 1998), further pointing to the necessity of Dnmt1 in 
maintaining genomic integrity.  
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My RNA-Seq data showed increased expression of the p53 target p21, which has an 
established role in activating the G1/S and G2/M phase checkpoints and inducing cellular 
senescence (Table 3.1 and Figure 3.6 D) (Deng, Zhang et al. 1995, Bunz, Dutriaux et al. 1998). 
p21 is often increased in response to DNA damage, and inhibits the transcription of many genes 
involved in cell cycle progression, leading to cell cycle arrest (Chang, Watanabe et al. 2000). 
Furthermore, p21 has been shown to be upregulated in response to loss of Dnmt1 in CRC cell 
lines (Chen, Hevi et al. 2007), and several studies suggest that p21 expression is controlled by 
DNA methylation (Allan, Duhig et al. 2000, Zhu, Srinivasan et al. 2003, Brenner, Deplus et al. 
2005). Immunostaining confirmed an increase in p21 protein levels in the Dnmt1-ablated 
intervillus epithelium compared to control progenitor cells, while p21 levels in postmitotic villus 
cells were comparable between the two genotypes (Figure 3.7 F-I). Taken together, my 
transcriptome and immunostaining analyses suggest that Dnmt1-deficient cells undergo cell cycle 
arrest.  
To further interrogate the extent of hypomethylation and the mechanism underlying the 
Dnmt1loxP/loxP;VillinCre mutant phenotype, I performed laser capture microdissection (LCM) and 
targeted bisulfite sequencing near the promoter regions of Atm, Chek2, p21, and Mlh1. I 
examined the methylation near the transcription start site (TSS) of these genes, but due to the 
presence of CpG islands in the proximal promoters of all four genes, the baseline methylation 
levels in controls were only 0-5% (data not shown). Next, I analyzed low-density CpGs clusters in 
putative regulatory regions 2 to 4 kb upstream of the respective transcription start site, and found 
that in all four cases the regions analyzed were significantly demethylated in the Dnmt1-deficient 
gut epithelium compared to control (Figure 3.9). The drastic loss of DNA methylation correlated 
with either increased or decreased mRNA levels, depending on the specific gene (Table 3.1 and 
Figure 3.6 C-D), suggesting that the upstream regulatory elements analyzed might function as 
enhancer (p21) or silencer (Chek2, Atm, Mlh1) regions (Jones and Takai 2001).  
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Dnmt1 ablation results in increased DNA damage and apoptosis in the progenitor zone 
Given the activation of apoptosis reported in other models following loss of Dnmt1 (Li, 
Bestor et al. 1992, Jackson-Grusby, Beard et al. 2001, Chen, Hevi et al. 2007), I investigated the 
levels of apoptosis and DNA damage in mutant intestinal progenitors. In control progenitor 
regions, as expected, there were no apoptotic cells, as dying epithelial cells are normally confined 
to the villus tip (Figure 3.10 A) (Hall, Coates et al. 1994). Surprisingly, I found a significant 
number of apoptotic progenitor cells in mutant tissue (Figure 3.10 B), increased more than fifty-
fold relative to littermate controls (Figure 3.10 C). To evaluate if increased apoptosis was 
confined to Dnmt1-deficient, non-replicating intervillus cells, I co-stained to confirm loss of Ki67 in 
TUNEL-positive areas (Figure 3.11 A-F). These data demonstrate that ablation of Dnmt1 not only 
blocks proliferation, but also induces cell death in the progenitor compartment of the perinatal 
intestine. The variability in the amount of cells undergoing apoptosis at any one point in time 
reflects the stochastic cell death observed in the global Dnmt1-mutant embyros (Li, Bestor et al. 
1992, Jackson-Grusby, Beard et al. 2001), but may also be due to the action of Cre in progenitor 
cells at different points during development. 
I considered the possibility that apoptosis of Dnmt1-deficient progenitors might be the 
result of activation of the DNA damage response. Hypomethylation causes genomic instability 
and increased mutation rates, which can lead to activation of cell cycle checkpoints and the DNA 
damage response (Chen, Pettersson et al. 1998, Chen, Hevi et al. 2007, Loughery, Dunne et al. 
2011). In addition, my own data demonstrate increased p21 levels in Dnmt1-mutant intervillus 
cells (Figure 3.7 G-H), which indicates cell cycle arrest. To assess DNA damage response 
activation in our mutants directly, I stained for γH2AX foci, which accumulate at double-stranded 
DNA breaks (Figures 3.10 D-E and 3.11 G-L). I found a more than 1,000-fold increase in γH2AX 
foci (p<0.001) in the mutant intervillus intestinal epithelium relative to littermate controls (Figure 
3.10 F, compare red brackets in 3.10 D&E).  These results indicate loss of Dnmt1 causes 
increased DNA damage, cell cycle arrest, and subsequent cell death. 
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Adult Dnmt1-ablated crypt cells maintain methylation of DNA damage response genes 
Given the opposing phenotypes we describe above for the neonatal intestine versus that 
observed in mice with Dnmt1 ablation in the adult gut epithelium (Sheaffer, Kim et al. 2014), I also 
analyzed DNA methylation in the adult crypt epithelium. Global methylation of repetitive LINE1 
elements and the imprinted H19 locus is reduced in adult mice with intestinal epithelial-specific 
Dnmt1 ablation to about the same extent as that seen in the perinatal ablation model described 
here (compare Figure 3.12 A-B to 3.3 G-H). Strikingly, however, p21 and Chek2 are not 
demethylated in the adult Dnmt1 ablation model (Figure 3.12 C-D), and Atm is only significantly 
demethylated when comparing the entire sequenced region relative to control crypt epithelium 
(Figure 3.12 E). Mlh1 is demethylated to a greater extent than the other genes analyzed (Figure 
3.12 F), indicating that Mlh1 is particularly sensitive to loss of Dnmt1. These results demonstrate 
that loss of Dnmt1 in the adult epithelium is not equivalent to the loss of Dnmt1 in the neonatal 
epithelium. I postulate that the differing requirement for Dnmt1 maintenance DNA methylation 
between the adult crypt compartment and the intervillus regions of the neonatal gut might be 
related to the more than 2-fold higher fractional proliferation rate of the latter compared to the 
former (Figure 3.13; (Itzkovitz, Blat et al. 2012)). I next sought to determine the differential 
requirement for Dnmt1 in developing versus mature intestinal epithelial crypts in an in vitro 
organoid culture system. 
 
Dnmt1 is required for establishing organoids in vitro 
 To demonstrate that Dnmt1 is required for organoid crypt culture from perinatal intestine, 
I employed EDTA-disassociation to isolate intestinal epithelia from postnatal day 1 (P1) 
Dnmt1loxP/loxP;VillinCre mutants and Dnmt1loxP/loxP littermate controls (Figure 3.10 G). I grew these 
perinatal organoid cultures in Matrigel with the ‘ENR’ (EGF, Noggin, R-Spondin) growth factor 
cocktail, allowing me to observe the development and maintenance of the perinatal intestinal 
epithelium in real time (Sato, Vries et al. 2009). I counted the number of organoids per well on 
days 3-5 of culture, and observed very few organoids (<10 per well) established from the 
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Dnmt1loxP/loxP;VillinCre mutant intestinal epithelium compared to the robust establishment of 
organoids (>150 per well) from control gut (Figure 3.10 H). On day 4, I observed nascent buds in 
the control Dnmt1loxP/loxPorganoids (Figure 3.10 K), but little sustained growth from the 
Dnmt1loxP/loxP;VillinCre mutant organoids (Figure 3.10 L). By day 5, it was apparent that no 
healthy, budding organoids were produced from the Dnmt1-mutant intestine relative to littermate 
controls (Figure 3.10 H,M,N). These results strongly support my in vivo data showing that Dnmt1 
is essential to maintain perinatal intestinal progenitor cells.  
To further probe the mechanism underlying the difference between the neonatal and 
adult Dnmt1-ablation phenotypes, I employed Dnmt1loxP/loxP;VillinCreERT2 (Sheaffer, Kim et al. 
2014) mice for in vitro organoid experiments. The VillinCreERT2 transgene allows temporal 
control of Dnmt1 ablation via addition of 4-hydroxytamoxifen (4OHT) to cells in culture. I 
hypothesized that Dnmt1 might be necessary for establishing the crypt compartment in neonatal 
mice, but not be required for the maintenance and survival of mature crypts in adult mice. To test 
this hypothesis, I isolated crypts from adult Dnmt1loxP/loxP and Dnmt1loxP/loxP;VillinCreERT2 mice, 
and ablated Dnmt1 at two different time points during organoid growth. In one set of experiments, 
I added 4OHT during the first two days of culture, when organoids are growing but have not yet 
established buds and crypt structures (Sato, Vries et al. 2009) (Figure 3.14 A). For the second set 
of experiments, I added 4OHT on days 5-7 of culture, after organoids had established proper 
crypt hierarchy in budding outgrowths (Sato, Vries et al. 2009) (Figure 3.15 A). 
In the “early” experiments, in which Dnmt1 had been acutely ablated by addition of 
4OHT, Dnmt1-deficient organoids failed to grow beyond small cyst-like structures, while control 
organoids began to exhibit buds by day 4 (Figure 3.14 B-E). Dnmt1 immunostaining confirmed 
loss of the enzyme in 4OHT-treated VillinCreERT2+ organoids (Figure 3.14 I). Addition of EdU to 
media 2 hours prior to cell harvest allowed analysis of replication rate. There were almost no 
EdU+ cells in the 4OHT-treated, Dnmt1-ablated organoids, in contrast to controls in which 
replicating cells were abundant (Figure 3.14 J-M). TUNEL staining demonstrated an increase in 
the frequency of TUNEL+ apoptotic nuclei in surviving Dnmt1-ablated organoids compared to 
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controls (Figure 3.14 N-Q). Overall, the loss of Dnmt1 during the establishment of organoid 
cultures parallels the phenotype seen in the perinatal Dnmt1loxp/lxop; VillinCre mutant intestine, 
strongly suggesting a unique role for Dnmt1 in crypt development. 
In stark contrast, the addition of 4OHT on days 5-7 of organoid culture, after large, multi-
crypt organoids had formed, had little effect on the growth and replication of mature organoids 
(Figure 3-15 B-E and J-M). I confirmed loss of Dnmt1 in 4OHT-treated, VillinCreERT2+ organoids 
by immunohistochemistry (Figure 3.15 F-I). Additionally, TUNEL staining demonstrated no 
increase in apoptosis rate in the 4OHT-treated, Dnmt1-ablated mature organoids (Figure 3.15 N-
Q). These results support my hypothesis that Dnmt1 performs unique functions in the developing 
intestinal epithelium, and plays a role in the establishment but not maintenance of crypts 
postnatally. 
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Discussion 
  
Taken together, my RNA-Seq, immunostaining, and organoid data reveal a crucial role 
for Dnmt1 in maintaining DNA methylation patterns, genomic stability, and progenitor cell status 
during intestinal development in vivo. I observed significant genome-wide DNA demethylation by 
targeted bisulfite sequencing of the LINE1 locus and the H19 ICR (Figure 3.3 G-H). My RNA-Seq 
and immunostaining data demonstrate that Dnmt1-deficient progenitors express decreased levels 
of genes essential for mitosis and chromosome segregation (Table 3.1 and Figure 3.7 C), and 
have increased rates of double-strand breaks (Figure 3.10 D-F). An increased rate of double-
strand breaks during the S-Phase of the cell cycle activates the G1/S checkpoint, mediated by 
p53 and p21. Indeed, increased p21 expression in the Dnmt1-deficient epithelium indicates that 
this checkpoint is active in mutant cells (Figures 3.10 G-H and 3.6 D). However, downstream 
targets of the DNA damage response pathway, including Atm, Chek2, and Mlh1, exhibit 
decreased expression by RNA-Seq (Table 3-1 and Figure 3.6 C), suggesting that Dnmt1-deficient 
intestinal progenitor cells are unable to activate the normal response to accumulated DNA 
damage. As a result, these Dnmt1-deficient progenitors undergo apoptosis, which leads to global 
loss of the intestinal epithelium (Figure 3.10 A-C). These findings are supported by previous 
studies implicating a requirement for Dnmt1 in DNA replication (Knox, Araujo et al. 2000), the 
DNA damage response (Mortusewicz, Schermelleh et al. 2005, Unterberger, Andrews et al. 2006, 
Loughery, Dunne et al. 2011), and cell cycle arrest (Chen, Hevi et al. 2007). 
My results demonstrate an essential role for Dnmt1 in maintaining epithelial genomic 
integrity during perinatal intestinal development. Interestingly, when I ablated Dnmt1 in the adult 
intestinal epithelium using a tamoxifen-inducible VillinCreERT2 transgene, I did not see a 
requirement for Dnmt1 in crypt cell survival, despite demethylation at the LINE1 locus (Figure 
3.12 A) (Sheaffer, Kim et al. 2014). These opposing phenotypes raise several questions. It is 
possible that in the adult intestinal epithelium, loss of Dnmt1 protein is compensated for by the de 
novo methyltransferases Dnmt3a and Dnmt3b. Alternatively, the unique requirement for Dnmt1 in 
newborn mice may be due to the significantly increased replication rate of neonatal progenitors 
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compared to adult crypt cells (Itzkovitz, Blat et al. 2012). As shown in Figure 3.13, the neonatal 
intestinal epithelium displays twice the fractional proliferation rate than that of adult mice. Thus, I 
hypothesize that as the neonatal Dnmt1-ablated cells divide their DNA methylation levels are 
rapidly reduced, and Dnmt3a and Dnmt3b do not compensate this loss. The high rate of 
proliferation in the neonatal intestine also distinguishes these findings concerning the developing 
intestine from studies of neuroblasts (Fan, Beard et al. 2001) or embryonic pancreas (Georgia, 
Kanji et al. 2013).  
Another possibility to explain the diverging phenotypes of adult and neonatal intestinal 
Dnmt1-ablation is that DNA methylation might not be crucial for cell survival and function in the 
mature crypt architecture. This explanation is supported by our organoid culture experiments 
(Figures 3.10 G-N, 3.14, and 3.15). The perinatal Dnmt1-deficient intestine fails to successfully 
produce organoids, in contrast to littermate controls (Figure 3.10 G-N). To test the differing 
requirements for Dnmt1 during organoid crypt development and maintenance, I used the 
inducible Dnmt1loxP/loxP;VillinCreERT2 system (Sheaffer, Kim et al. 2014). When Dnmt1 was 
ablated before budding structures appear, organoids failed to thrive and eventually died (Figure 
3.14). However, ablation of Dnmt1 after organoid buds and the ISC niche are established had 
little effect on the maintenance of replicating progenitors (Figure 3.15).  
Several recently published studies analyze the differences between fetal progenitors and 
adult ISCs (Fordham, Yui et al. 2013, Mustata, Vasile et al. 2013). Fordham and colleagues 
report that intestinal progenitor cell maturation correlates with increased Wnt signaling. In their 
study, Lgr5+ cells isolated from neonatal intestine produced budding organoids, with high 
expression of adult stem cell markers. Lgr5- cells isolated from the same neonatal tissue formed 
fetal enterospheres (FENs), which expressed low levels of Wnt factors and ISC markers, and did 
not display budding activity. My results strongly support the notion that adult and perinatal 
intestinal progenitors are not equivalent populations, and have differential requirements for cell 
maintenance.  
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In conclusion, I have demonstrated an important role for Dnmt1 in establishing intestinal 
epithelial crypts following birth. I suggest that Dnmt1 is essential during the first few weeks of life 
to maintain genomic methylation patterns during this period of intense cellular proliferation and 
villus growth, and to prevent genome alterations that lead to progenitor cell death. Future 
research in this field should focus on the varying requirements for DNA methylation during 
development, particularly in supporting genomic stability and proliferation during organ 
development, in contrast to those necessary in adulthood.  
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Figure 3.1. Time course of Dnmt1 localization during intestinal epithelial development.  
(A-D) Dnmt1 is expressed in the intervillus regions during late fetal development, and becomes 
restricted to crypts in the adult intestine. Dnmt1 protein stain is brown; hematoxylin nuclear 
counterstain is blue. Scale bars are 50 µm.  
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Figure 3.2. Embryonic Dnmt1loxP/loxP;VillinCre intestine is highly mosaic for Dnmt1 ablation, 
while the adult Dnmt1loxP/loxP;VillinCre is repopulated by cells that have escaped Cre-
mediated Dnmt1 ablation.  
(A-C) E18.5 mutants showed variable levels of Dnmt1-ablation, with the majority of intervillus 
regions retaining expression of Dnmt1 protein (B,C). (D,E) Dnmt1 immunohistochemistry in 
controls and mutants at 3 months of age revealed that mutant intestines are predominantly 
Dnmt1+. Scale bars are 50 µm.  
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Figure 3.3. Ablation of Dnmt1 in the developing intestinal epithelium causes reduced 
proliferation and DNA hypomethylation.  
(A) Only 35% of Dnmt1loxP/loxP;VillinCre mutants survived to postnatal day 20 (P20) (n=14). (B) P0 
mutants have significantly fewer villi relative to littermate controls (n=4). (C,E) Dnmt1 protein 
immunohistochemistry, (D,F) Ki67 protein immunohistochemistry. P0 mutants display mosaic 
Dnmt1 ablation compared to controls (C,E). Absence of Dnmt1 (E, red brackets) corresponds to 
loss of proliferation in mutant progenitors as assessed by Ki67 staining of adjacent section (F, red 
brackets). Dnmt1+ progenitors show similar proliferation in mutants (black bars E,F) compared to 
controls (D). (G) LINE1 repeat DNA methylation levels as assessed by bisulfite-sequencing (n=4). 
Decreased LINE1 methylation indicates global demethylation in Dnmt1 mutant progenitor cells 
compared to controls. (H) H19 imprinting control region (ICR) DNA methylation levels are 
decreased in mutant progenitor cells relative to controls (n=4). For all graphs, data are 
represented as mean ± SEM. *P<0.05; **P<0.01; ***P<0.001, two-tailed Student’s t-test. Scale 
bars are 50 µm. 
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Figure 3.4. Dnmt3a and Dnmt3b are not upregulated in Dnmt1loxP/loxP;VillinCre neonatal 
mutants.  
(A,B) Immunohistochemistry for Dnmt1 in Dnmt1loxP/loxP controls and Dnmt1loxP/loxP;VillinCre 
mutants. (C) qRT-PCR of whole neonatal proximal jejunum showed a significant decrease in 
Dnmt1 transcript in mutants compared to littermate controls. (D-E,G-H) Immunostaining on serial 
sections demonstrated no change in Dnmt3a (green, second row) and Dnmt3b (red, third row) 
localization. (F,I) qRT-PCR does not reveal a significant difference in Dnmt3a or Dnmt3b gene 
expression. In all images, scale bars are 50 µm. For all qRT-PCR, control n=10, mutant n=12. 
Data are represented as mean ± SEM. ***P<0.001, two-tailed Student’s t-test. 
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Figure 3.5. Dnmt1 and Ki67 protein are co-localized in the intervillus progenitor zone.  
(A-D) Co-staining for Dnmt1 (A,B) and Ki67 (C,D) using separate imaging of each protein on the 
same section revealed strong overlap of Dnmt1 and Ki67 proteins in controls (A,C). 
Dnmt1loxP/loxP;VillinCre epithelial cells with Dnmt1 ablation (B), do not express Ki67 (D). In all 
images, scale bars are 50 µm.  
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Figure 3.6. Collection of Dnmt1-ablated progenitors cells by Laser Capture 
Microdissection (LCM).  
(A) Gene expression levels of Dnmt3a, Dnmt3b, and mKi67 from RNA-Seq data. Fold change is 
relative to control. (B) RNA-Seq expression of Dnmt1 exon 5, which is excised upon Cre 
activation, indicates a nearly 90% reduction in Dnmt1 mRNA levels in the LCM tissue of 
Dnmt1loxP/loxP;VillinCre compared to controls (RPM, Reads per Million). (C,D) We performed 
additional LCM to confirm RNA-Seq data in independent biological replicates (Dnmt1loxP/loxP 
controls, n=4; Dnmt1loxP/loxP;VillinCre mutants, n=3). (C) qRT-PCR confirmation of genes that are 
misregulated in RNA-Seq data: Dnmt1, Chek2, Atm, Mcm10, Cdk2, Mlh1, Foxm1, and Lyz. (D) 
Validation of p21 expression levels, which is upregulated in our RNA-Seq data. qRT-PCR data 
are presented normalized to the geometric mean of 5 reference genes: Tbp, B2m, β-actin, Polr2b, 
and Rplp0. (B-D) Data are represented as mean ± SEM. *P<0.05, **P<0.01, one-tailed Student’s 
t-test. 
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Figure 3.7. RNA-Seq analysis reveals decreased expression of crucial cell-cycle regulators 
in Dnmt1-deficient progenitor cells.  
(A, B) Collection of intervillus regions (encircled) before (A) and after (B) laser capture 
microdissection (LCM). (C) DAVID gene ontology analysis of genes with transcripts are 
downregulated in Dnmt1-deficient epithelial cells as determined by RNA-Seq. (D,E) Co-staining 
for Ki67 (green) and lysozyme (red) in control and Dnmt1 mutant intestine. A fraction of non-
replicating Dnmt1-negative cells exhibit increased lysozyme protein levels (E, arrows), a marker 
for Paneth cell differentiation, relative to controls (D). (F,G) Immunohistochemistry (IHC) showing 
that in controls p21 protein is confined to differentiated cells in the villus; in Dnmt1 mutants, 
expression is strikingly increased in intervillus regions (black bracket in F versus red bracket in 
G). (H,I) Dnmt1 immunohistochemistry on serial sections confirms Dnmt1 ablation in cells 
indicated by red brackets in G,I. In all images, scale bars are 50 µm.  
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Table 3.1. Genes differentially expressed between Dnmt1loxP/loxP;VillinCre and Dnmt1loxP/+ 
intestine.  
RNA-Seq data from LCM tissue for genes of interest. Fold change indicates expression levels 
relative to control. FDR<0.1. 
  
	   	    80	  
  
	   	    81	  
Figure 3.8. Enterocyte, enteroendocrine, Paneth, and goblet cell populations in 
Dnmt1loxP/loxP;VillinCre mutants.  
(A-B, E-F, I-J, M-N) Dnmt1 immunohistochemistry on serial sections confirms loss of Dnmt1 in 
the mutant regions analyzed. (A-D) Alkaline phosphatase (AP) staining for absorptive enterocytes 
revealed a small increase in AP+ mutant progenitor cells (black arrowheads in D) relative to 
controls (C). (E-H) Chromogranin A (ChgA) staining for enteroendocrine cells revealed a small 
increase in ChgA+ progenitor cells in mutants (H, white arrow) compared to controls (G). (I-L) Co-
staining for Ki67 (green) and lysozyme (red) in control and Dnmt1 mutant intestine. Non-
replicating Dnmt1-mutant progenitors had increased lysozyme protein (L, white arrows), a marker 
for Paneth cell differentiation, relative to controls (K). (M-P) Mucin2 staining showed similar 
staining patterns of goblet cells in control (O, circled cells) and Dnmt1 mutant (P, circled cells) 
progenitor zones. In all images, scale bars are 50 µm.  
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Figure 3.9. Key DNA damage response genes are significantly demethylated in Dnmt1-
ablated perinatal intestinal epithelial progenitors.  
(A-D) Targeted bisulfite-sequencing analysis of DNA damage response genes demonstrates 
significant demethylation upstream of p21 (A), Chek2 (B), Atm (C), and Mlh1 (D) in 
Dnmt1loxP/loxP;VillinCre mutants compared to littermate controls. Beneath each bar chart is a 
diagram indicating the position of the transcription start site (TSS, arrow) and CpG islands relative 
to the regions sequenced. Each region is ~2-4 kb upstream of the TSS. For all graphs, error bars 
are ± SEM, **P<0.01, ***P<0.001, two-tailed Student’s t-test. 
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Figure 3.10. Ablation of Dnmt1 in the immature intestine results in loss of progenitor cells 
via apoptosis both in vivo and in vitro.  
(A,B) TUNEL staining in red, E-cadherin in green, DAPI in blue. TUNEL staining demonstrates 
increased levels of apoptosis in Dnmt1 mutant progenitor cells (A) compared to control (B). (C) 
TUNEL-positive intervillus nuclei within 20 µm from the epithelial base (red vertical bars in A,B) 
were quantified in Dnmt1 mutants and littermate controls (n≥5). (D-F) Dnmt1 mutant progenitors 
(E) have increased DNA double strand breaks compared to controls (D), as determined by 
γH2AX staining. (F) Quantification of γH2AX+ cell number as performed for TUNEL+ cells (n=4); 20 
µm vertical bar shown in (D,E). (G) Experimental outline for postnatal day 1 (P1) Dnmt1loxP/loxP 
(n=3) and Dnmt1loxP/loxP;VillinCre (n=2) intestinal organoid cultures. (H) Average number of 
organoids per well during timecourse experiment. Organoids were grown in triplicate for each 
biological replicate. (I-N) Live phase contrast imaging of Dnmt1loxP/loxP control and 
Dnmt1loxP/loxP;VillinCre mutant organoids on each day of culture. Surviving mutant organoids on 
day 5 persisted as very small cysts (N), while controls were considerably larger and exhibited 
budding activity (M). Phase contrast images were all captured at 10X. For all graphs, error bars 
are ± SEM. *P<0.05, **P<0.01, ***P<0.001, two-tailed (C,F) or one-tailed (H) Student’s t-test. 
Scale bars are 50 µm. 
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Figure 3.11. Apoptosis and DNA damage in Dnmt1loxP/loxP;VillinCre mutant mice are 
confined to the non-replicating intervillus epithelium.  
(A-F) Co-staining for Ki67 (green, A,D) with TUNEL (red, B,E) in control (A-C) and Dnmt1-
mutants (D-F). Mutant progenitor zones harbor TUNEL+ apoptotic cells that correspond with 
Ki67-negative non-proliferative regions (D-F). (G-M) γH2AX co-stained with Ki67 revealed that 
control epithelium does not contain DNA-damaged cells in the progenitor zone (G-I). Ki67-
negative, mutant progenitors cells have increased levels of DNA damage (J-L). Scale bars are 50 
µm. 
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Figure 3.12. Dnmt1loxP/loxP;VillinCreERT2 adult crypt epithelial cells are demethylated at the 
LINE1 locus, but not at DNA damage response genes.  
(A) LINE1 repeat DNA methylation levels as assessed by bisulfite-sequencing. Decreased LINE1 
methylation suggests global demethylation in Dnmt1-ablated adult crypt cells relative to controls. 
(B) In the H19 imprinting control region (ICR), DNA methylation levels are slightly decreased in 
adult Dnmt1-mutant crypt cells relative to controls. (C-F) Targeted bisulfite-sequencing analysis of 
DNA damage response genes revealed similar levels of DNA methylation in adult Dnmt1-ablated 
crypt cells compared to controls. (C,D) p21 (Cdkn1a) and Chek2 are not differentially methylated 
in adult Dnmt1-mutant crypts. Atm (E) and Mlh1 (F) show an overall decrease in DNA methylation 
relative to control, but are not significantly altered at each CpG analyzed. Beneath bar charts (C-
F) is a diagram indicating the position of the transcription start site (TSS, arrow) and CpG islands 
relative to the regions sequenced. Each region is ~2-4 kb upstream of the TSS. Mutant n=5; 
Control n=2. Data are represented as mean ± SEM, **P<0.01, ***P<0.001, two-tailed Student’s t-
test. 
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Figure 3.13. Neonatal intervillus regions display increased rate of replication compared to 
adult crypts.  
(A,B) Representative images of adult (A, n=5) and postnatal day 0 (B, n=12) jejunum stain for 
EdU following a 2-hour EdU pulse (red). (C) Percent of EdU+ cells per crypt-villus subunit is 
approximately two-fold higher in the neonatal compared to the adult jejunum. Rates calculated as 
percent EdU+ nuclei of total nuclei between two adjacent villi peaks. Scale bars are 50 µm. Data 
are represented as mean ± SEM. ***P<0.001, two-tailed Student’s t-test. 
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Figure 3.14. Dnmt1 is required to establish intestinal organoid cultures.  
(A) Time course of 4OHT treatment in organoids from Dnmt1loxP/loxP and 
Dnmt1loxP/loxP;VillinCreERT2 adult intestine to test the requirement for Dnmt1 in establishment of 
intestinal crypts in vitro. (B-Q) Immunohistochemical analysis of organoids described in (A). (B-E) 
Live phase contrast imaging demonstrates reduced size and budding activity of Dnmt1-ablated 
organoids (E) compared to controls (B-D). All phase contrast images were captured at 10X. (F-I) 
Dnmt1 protein is reduced in Dnmt1loxP/loxP;VillinCreERT2 organoids upon treatment with 4OHT (I), 
relative to control organoids (F-G). (J-M) 2 hour EdU treatment shows reduced replication rate of 
Dnmt1-mutant organoids (M) compared to controls (J-L). (N-Q) Dnmt1-ablated organoids (Q) 
display increased apoptosis (white arrowheads) relative to non-treated controls (N,P). 
Additionally, apoptosis is not increased in control Dnmt1loxP/loxP organoids treated with 4OHT (O). 
All scale bars are 50 µm.  
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Figure 3.15. Dnmt1 is not necessary to maintain established intestinal organoid cultures. 
(A) Time course of 4OHT treatment to test requirement for Dnmt1 in maintenance of intestinal 
crypts in vitro. (B-Q) Immunohistochemical analysis of organoids described in (A). (B-E) Live 
phase contrast imaging demonstrates similar size of Dnmt1-ablated organoids (E) at day 9 of 
culture relative to 4OHT-treated (C) and non-treated (B,D) controls. All phase contrast images 
were captured at 10X. (F-I) Confirmation of Dnmt1 protein depletion in 4OHT-treated 
Dnmt1loxP/loxP;VillinCreERT2 organoids (I) compared to controls (F-H). (J-M) A 2-hour pulse of 
EdU reveals preserved replication of Dnmt1-mutant organoids (M), similar to that observed in 
control organoids (J-L). (E,I) Dnmt1-ablated organoids do not display any changes in apoptosis 
(Q) compared to treated (O) or non-treated (N,P) control organoids. TUNEL positive material in 
(P,Q) is typical debris accumulation within organoids. All scale bars are 50 µm. 
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Chapter 4 
 
Dnmt1 and Dnmt3b are required for genomic stability in 
intestinal epithelial homeostasis 
 
 
 
 
 
  
	   	    97	  
Abstract   
 Colorectal cancer (CRC) is a heterogeneous disease accompanied by a sequence of 
genetic mutations and epigenetic changes. DNA methylation is thought to drive CRC progression 
by the repression of tumor suppressor genes via promoter methylation. The DNA 
methyltransferase Dnmt1 is required for appropriate expression of stem cell genes and 
differentiation of the intestinal epithelium. Using temporally controlled intestinal epithelial-specific 
gene ablation, I show that loss of Dnmt1 in the ApcMin/+ mouse model of intestinal cancer 
surprisingly causes accelerated, not delayed, adenoma formation. Loss of Dnmt1 precipitates an 
acute response characterized by hypomethylation of repetitive elements, genomic instability, and 
apoptosis, which is followed by remethylation with time. This recovery is entirely dependent on 
the activity of the de novo methyltransferase Dnmt3b. In light of these data, the current dogma 
regarding the role of DNA methylation in colon cancer needs to be revisited. 
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Introduction 
 Colorectal cancer (CRC) is a multifactorial disease with various inputs including diet, 
environment, genetic mutations, and epigenetic abnormalities. The disease first manifests as an 
over-proliferation defect in the form of polyps that, if not removed, can progress to precancerous 
adenomas. Further transition to invasive and metastatic cancer is due to the accumulation of 
multiple genetic mutations and epigenetic changes that alter gene expression patterns, driving 
neoplastic transformation and growth (Fearon 2011). However, the extent to which epigenetic 
modifications, and specifically DNA methylation, contribute to the initiation and progression of 
CRC is unclear.  
 DNA methylation patterns are established by DNA methyltransferase enzymes (Dnmts), 
of which there are two categories. The ‘maintenance’ methyltransferase, Dnmt1, has a high 
affinity for hemi-methylated DNA in vitro, and preserves DNA methylation in replicating cells. The 
‘de novo’ methyltransferases, Dnmt3a and Dnm3b, establish novel patterns of DNA methylation, 
and prefer to bind unmethylated DNA in vitro. DNA methylation is generally found in the context 
of CpG dinucleotides in mammals, and while most of the genome is highly methylated, promoter 
and distal regulatory regions display low levels of DNA methylation (Stadler, Murr et al. 2011, 
Ziller, Gu et al. 2013, Sheaffer, Kim et al. 2014). Regulatory regions also exhibit the most 
dynamic DNA methylation among distinct tissue types, and are commonly hypomethylated in 
cancer (Irizarry, Ladd-Acosta et al. 2009, Stadler, Murr et al. 2011, Ziller, Gu et al. 2013). 
Comparison of human colon adenomas to control tissue revealed that although proximal 
promoter CpG islands are generally hypermethylated in tumors, DNA hypomethylation is found 
genome-wide, including at neighboring CpG island shores, intergenic regions, and repetitive 
elements (Berman, Weisenberger et al. 2012, Luo, Wong et al. 2014).  
DNA methylation is critical for intestinal epithelial homeostasis (Sheaffer, Kim et al. 2014, 
Elliott, Sheaffer et al. 2015). Intestinal stem cells are located in the crypt and respond to multiple 
signaling pathways that control proliferation and differentiation (Sheaffer and Kaestner 2012). 
Loss of Dnmt1 in the mouse intestine causes hypomethylation of regulatory regions associated 
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with several intestinal stem cell genes, resulting in inappropriate activation during differentiation, 
and expansion of the crypt zone (Sheaffer, Kim et al. 2014). Many intestinal stem cell factor 
genes, such as LGR5, OLFM4, and HES1, are also highly expressed in human colon cancer (van 
der Flier, Haegebarth et al. 2009, Chen, Zhang et al. 2014, Gao, Zhang et al. 2014). These data 
suggest that DNA hypomethylation may play an important role in intestinal cancer progression. 
Previously, the role of Dnmt1 in intestinal tumorigenesis was studied in the ApcMin/+ 
mouse model. This paradigm mimics the hereditary human colon cancer syndrome Familial 
Adenomatous Polyposis (FAP), which is caused by germline mutations of the APC gene (Su, 
Kinzler et al. 1992). Loss of heterozygosity (LOH) at the APC locus causes β-catenin stabilization 
and unrestricted Wnt activity, resulting in the formation of microadenomas, which progress to 
large adenomas over time. Multiple hypomorphic Dnmt1 paradigms show complete block of 
macroscopic tumor formation (Laird, Jackson-Grusby et al. 1995, Cormier and Dove 2000, Eads, 
Nickel et al. 2002, Trasler, Deng et al. 2003, Yamada, Jackson-Grusby et al. 2005). The authors 
concluded that Dnmt1 and DNA methylation are required for adenoma development in the 
ApcMin/+ model. These studies employed hypomorphic Dnmt1 mice, which express constitutively 
reduced Dnmt1 levels from earliest development onward in all tissues (Laird, Jackson-Grusby et 
al. 1995), including non-epithelial cells, such as myofibroblasts. Mesenchymally expressed genes 
have been shown to be strong modifiers of the ApcMin/+ tumor load (Perreault, Sackett et al. 2005), 
and could thus contribute to the observed phenotype in the Dnmt1-hypomorphic ApcMin/+ intestine. 
Due to these limitations, the precise mechanism of how DNA methylation acts within the intestinal 
epithelium during adenoma initiation and progression remains to be determined.  
To address this important knowledge gap, I employed a temporally controlled, intestinal 
epithelial-specific gene ablation model to delete Dnmt1 and decrease maintenance DNA 
methylation. I find that deletion of Dnmt1 causes accelerated loss of heterozygosity at the Apc 
locus, with a dramatic increase in adenoma initiation and progression. Ablation of Dnmt1 causes 
a severe acute phenotype characterized by global DNA hypomethylation, genome instability, and 
apoptosis. Contrary to the current dogma, I demonstrate that the de novo methyltransferase 
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Dnmt3b is essential for epithelial recovery following Dnmt1 ablation, and provide evidence that 
Dnmt3b compensates for the maintenance methyltransferase in vivo. 
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Results 
 
Deletion of Dnmt1 in the intestinal epithelium of adult ApcMin/+ mice accelerates adenoma 
initiation. 
To determine the role of Dnmt1 in intestinal adenoma formation, I employed 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mice to inducibly delete Dnmt1 throughout the intestinal and 
colonic epithelia. ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mice and their ApcMin/+;Dnmt1loxP/loxP 
siblings were injected with tamoxifen to induce Dnmt1 deletion at four weeks of age (see 
experimental schema in Figure 4.1). At three months of age, the small intestine and colon were 
examined for neoplastic transformation. Dnmt1 deletion was effective throughout the mutant 
epithelia of small intestine and colon (Figures 4.2 A,B and 4.3 A,B). Surprisingly, hematoxylin and 
eosin staining revealed a dramatic increase in the number of neoplastic lesions throughout the 
entire Dnmt1-deficient small intestine, where mutants displayed >6-fold more macroscopic 
adenomas (Figure 4.2 C-E). 
Previously, it had been reported that partial loss of Dnmt1 produces a block in the 
progression of adenomas in the ApcMin/+ mouse paradigm (Laird, Jackson-Grusby et al. 1995, 
Cormier and Dove 2000, Eads, Nickel et al. 2002, Trasler, Deng et al. 2003, Yamada, Jackson-
Grusby et al. 2005), which is in sharp contrast to our finding of an increased number of 
macroscopic lesions in the ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 deletion model. To confirm that 
these lesions are bona fide adenomas, I performed histopathologic assessment on the intestines 
of three-month old ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 and ApcMin/+;Dnmt1loxP/loxP mice which had 
been tamoxifen treated at 4 weeks of age. Using criteria described by Biovin et al. (2003), I found 
15-fold more lesions that had progressed to adenomas in Dnmt1-deficient mice as compared to 
ApcMin/+ animals (Figure 4.2 F). In addition, Dnmt1-deficient small intestinal tumors were on 
average twice as large as those of controls (Figure 4.2 G).  
Adenoma formation in the ApcMin/+ mouse model is driven by loss of heterozygosity (LOH) 
at the Apc locus, which causes nuclear accumulation of β-catenin and activation of Wnt signaling. 
LOH is observed in virtually all ApcMin/+ intestinal tumors (Levy, Smith et al. 1994, Luongo, Moser 
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et al. 1994). Thus, increased tumor load likely reflects accelerated LOH at earlier time points. To 
establish if increased macroadenoma formation in three-month old Dnmt1-mutants correlated 
with earlier tumor initiation, I injected four-week old ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mice 
(mutant) and their ApcMin/+;Dnmt1loxP/loxP (control) siblings with tamoxifen, and examined the small 
intestine at two months of age for microadenomas (see schema in Figure 4.1). Mutant animals 
displayed an increase in microadenoma number in the small intestine compared to controls 
(Figure 4.2 H), even though lesions were still comparable in size (Figure 4.2 G). All lesions 
observed in two-month old animals showed similar histopathology and were characterized as 
gastrointestinal intraepithelial neoplasias (data not shown).  
Previous studies also reported increased colonic microadenomas in Dnmt1-hypomorphic 
ApcMin/+ mice (Yamada, Jackson-Grusby et al. 2005). To investigate microadenoma formation in 
the colon, I employed nuclear β-catenin staining to identify neoplastic lesions in three-month old 
mice. Only 14% of control mice displayed neoplastic transformation in the colon (n=7). However, 
58% of Dnmt1-deficient ApcMin/+ colons (n=12) showed at least one incidence of microadenoma, 
including several mice with multiple lesions (Figure 4.3 D). Since ApcMin/+ mice exhibit tumors 
predominantly in the small intestine (Moser, Pitot et al. 1990, Moser, Dove et al. 1992), I focused 
my studies on adenoma development and progression in the small intestinal epithelium. 
To characterize adenoma initiation by LOH in detail, I employed laser capture 
microdissection to isolate neoplastic and normal intestinal epithelial cells in tamoxifen-treated 
two- and three-month old ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mutant mice and their 
ApcMin/+;Dnmt1loxP/loxP control siblings. DNA was isolated from these samples (approximately 
1,000 cells per sample) and the status of the Apc alleles was examined as performed previously 
(Luongo, Moser et al. 1994). Analysis of control and mutant mice produced bands for both the 
wildtype Apc and the ApcMin alleles in the normal epithelium, as expected, while neoplastic 
lesions showed only the ApcMin allele band (data not shown).  
Several lines of evidence confirm that the numerous adenomas that develop in the 
Dnmt1-deficient ApcMin/+ mice are the result of Wnt pathway activation. Thus, 
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ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 (mutant) adenomas showed increased nuclear β-catenin 
protein (Figure 4.4 B,C), and multiple Wnt signaling targets, such as CycD1 (Figure 4.4 E,F) and 
Sox9 (Figure 4.4 H,I) were also strongly activated. These data demonstrate that total loss of 
Dnmt1 in the mature small intestinal epithelium promotes neoplastic progression, in stark contrast 
to what had been reported previously (Laird, Jackson-Grusby et al. 1995, Cormier and Dove 
2000, Eads, Nickel et al. 2002, Trasler, Deng et al. 2003, Yamada, Jackson-Grusby et al. 2005). 
 
Dnmt1-null adenomas display increased chromosome instability 
Due to the dramatic difference in lesion size and grade observed in three-month old 
animals, I investigated whether Dnmt1-deficiency had any impact on cell proliferation or death in 
ApcMin/+ adenomas. I analyzed ApcMin/+;Dnmt1loxP/loxP (control) and 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 (mutant) tumor proliferation using the cell cycle marker, Ki67 
(Figure 4.5 B-D). Non-tumor Dnmt1-deficient intestinal epithelium displayed a slight expansion of 
the crypt zone, as reported previously (Sheaffer, Kim et al. 2014). I also determined the 
percentages of control and mutant epithelial cells in M-phase by staining for phosphorylated-H3 
(PH3) (Figure 4.5 A). These data show that the proliferation rate was equivalent in Dnmt1-positive 
or -negative tumors, at both two months and three months of age. Furthermore, comparison of 
three-month old control and two-month old mutant adenomas revealed that similarly sized tumors 
had comparable rates of cellular proliferation (Figure 4.5 B,C). I also examined neoplastic cells for 
signs of cell death using terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), 
which detects DNA fragmentation in apoptotic cells. Both control and mutant adenomas exhibited 
only rare epithelial cells positive for TUNEL, and I found no difference in cell death between 
Dnmt1-mutant and control neoplastic epithelia. However, many subepithelial cells were TUNEL 
positive (Figure 4.5 E-G). These data demonstrate that loss of Dnmt1 in vivo has no effect on 
ApcMin/+ adenoma proliferation or cell death, and indicates that the increase in adenoma number 
and size found in three-month old Dnmt1-mutant mice is driven by accelerated tumor initiation 
through loss of heterozygosity. 
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I next investigated the requirement of Dnmt1 for chromosome stability in our intestinal 
cancer model. Global DNA hypomethylation correlates with chromosomal instability in CRC 
(Lengauer, Kinzler et al. 1997, Rodriguez, Frigola et al. 2006). I employed γH2AX staining to 
visualize DNA double-strand breaks as a marker of chromosomal instability, and found many 
more epithelial cells within Dnmt1-deficient adenomas to be γH2AX+ compared to control 
adenomas (Figure 4.5 H-J). Notably, γH2AX foci had already appeared in two-month old mutant 
adenomas that are of similar size to control three-month old adenomas (Figure 4.5 H,I). These 
data indicate that increased double strand breaks are not simply the consequence of rapid tumor 
growth, but an early event in tumorigenesis in the Dnmt1-deficient ApcMin/+ mouse.  
 
Dnmt1 deletion in ApcMin/+ mice causes massive epithelial remodeling within one week 
 To determine the underlying causes of accelerated loss of heterozygosity and increased 
tumorigenesis in the ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mutant intestine, I next focused on the 
earliest events following Dnmt1 ablation. To this end, I injected tamoxifen in four-week old 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mice (mutant) and their ApcMin/+;Dnmt1loxP/loxP, 
Dnmt1loxP/loxP;VillinCreERT2, and Dnmt1loxP/loxP siblings (controls), and examined the small 
intestine one week later (see Figure 4.1 for experimental schema). I confirmed loss of Dnmt1 
protein (Figure 4.6 E-H), and proceeded to gross histological analysis. Acute loss of Dnmt1 in 
Dnmt1loxP/loxP;VillinCreERT2 mice caused crypt expansion compared to controls (Figure 4.6 A-B), 
as described previously (Sheaffer, Kim et al. 2014). Although the 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mutant intestine exhibited crypt expansion, surprisingly, I 
also detected many areas that displayed a drastic loss of crypt and villus epithelium (Figure 4.6 
C-D). When I assessed proliferation by performing immunofluorescent staining for Ki67, the 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mutant intestine contained many crypts that had little to no 
Ki67 staining (compare Figure 4.6 L to 4.6 K), while crypts in Dnmt1loxP/loxP;VillinCreERT2 
intestine had an obvious increase in the proliferative zone (Figure 4.6 I-J). Additionally, I 
performed TUNEL staining to assess levels of apoptosis in ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 
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mutants and control siblings (Figure 4.6 M-P). Interestingly, I observed increased levels of crypt 
cell apoptosis in ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 (Figure 4.6 P) relative to all other conditions. 
These data indicate that loss of Dnmt1 on the ApcMin/+ background causes a severe acute 
phenotype of crypt loss not present in the Apc+/+, Dnmt1-deficient intestine.   
ApcMin/+ mice display increased sensitivity to DNA damage, including damage induced by 
ionizing radiation (Tao, Tang et al. 2015), and are also noted to have defects in epithelial cell 
migration (Mahmoud, Boolbol et al. 1997). I reasoned that loss of Dnmt1 might induce genome 
instability that many epithelial cells in ApcMin/+ mice are unable to repair. To determine basal levels 
of DNA damage in mice one week after tamoxifen administration, long before tumor formation 
has been initiated, I performed γH2AX staining (Figure 4.6 I-L). I discovered a dramatic increase 
in the fraction of γH2AX+ crypt cells in ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 (Figure 4.6 L) versus 
ApcMin/+ controls, which contained no γH2AX+ epithelial cells (Figure 4.6 K). These results 
demonstrate that genomic instability in ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mice occurs prior to 
accelerated tumorigenesis. Dnmt1loxP/loxP;VillinCreERT2 mutants also displayed low levels of 
γH2AX+ crypt cells, indicating that Dnmt1 is required to maintain genomic stability in proliferating 
intestinal cells (Figure 4.6 I,J).  
 
DNA methylation dynamics following Dnmt1 deletion  
Despite the striking acute phenotype I observed following Dnmt1 deletion in the adult 
ApcMin/+ intestinal epithelium, ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mutant mice survive to three 
months of age. I hypothesized that the dramatic loss of global DNA methylation following Dnmt1 
ablation precipitates acute genome instability, and that animal survival to three months correlates 
with recovery of DNA methylation levels. To test this hypothesis, I performed targeted bisulfite 
sequencing of the Long Interspersed Nucleotide Element 1 (LINE1) to estimate global DNA 
methylation levels, and of the H19 imprinting control region (ICR) to determine DNA methylation 
maintenance (Lane, Dean et al. 2003, Yang, Estécio et al. 2004, Samuel, Suzuki et al. 2009).  
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I employed laser capture microdissection to collect crypts from 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mutant and ApcMin/+;Dnmt1loxP/loxP control intestines one week 
following tamoxifen treatment (see schema in Figure 4.1). Strikingly, within one week following 
Dnmt1 deletion, I observed a 50% reduction in DNA methylation at the LINE1 loci in mutant 
crypts compared to control crypt epithelium (Figure 4.7 A). In contrast, methylation of the H19 
imprinting control region was maintained, indicating that maintenance methylation of imprinted 
loci was preserved in ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 intestinal epithelium (Figure 4.8 A).  
To assess recovery of global DNA methylation with time, I implemented laser capture 
microdissection to isolate the neoplastic and normal intestinal epithelia from 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mutant and ApcMin/+;Dnmt1loxP/loxP control intestines at three 
months of age, two months after tamoxifen administration. Surprisingly, I found no differences in 
methylation levels in all conditions tested, demonstrating that DNA methylation had been fully 
restored after acute loss following Dnmt1 ablation (Figure 4.7 B). I excluded the trivial explanation 
that Dnmt1-positive ‘Cre-escaper’ cells had repopulated the neoplastic epithelium by performing 
immunohistochemistry for Dnmt1 protein, confirming that these tumors were Dnmt1-negative 
(compare Figure 4.9 B to 4.9 A).  
I surmised that the de novo methyltransferases might compensate for the loss of Dnmt1, 
and performed immunofluorescent staining for both Dnmt3a and Dnmt3b one week following 
Dnmt1 deletion. While I observed no change in Dnmt3a levels by immunofluorescence (Figure 
4.10 A,B), I found Dnmt3b protein levels increased in five-week old 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 crypts compared to sibling controls (Figure 4.10 C,D). 
Overall, these data suggest a mechanism in which Dnmt3b is activated to compensate for loss of 
Dnmt1 in the intestinal epithelium. I next aimed to test this proposed compensation mechanism 
using mouse genetics. 
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Dnmt3b is required to maintain DNA methylation and epithelial integrity in the absence of 
Dnmt1 
  To directly test the requirement for Dnmt3b in maintaining DNA methylation in the 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 intestinal epithelium, I bred the Dnmt3bloxP/loxP allele (Lin, 
Yamada et al. 2006) onto the mutant genotype, producing 
ApcMin/+;Dnmt1loxP/loxP;Dnmt3bloxP/loxP;VillinCreERT2 mice, along with 
ApcMin/+;Dnmt1loxP/loxP;Dnmt3bloxP/loxP siblings as controls. In these cohorts of mice, I injected 
tamoxifen at four weeks of age to induce simultaneous ablation of Dnmt1 and Dnmt3b. I isolated 
small intestines one week following tamoxifen administration for phenotypic analysis. 
 Histological examination revealed a grossly altered epithelium in the 
ApcMin/+;Dnmt1;Dnmt3b mutant mice, with many areas lacking villi and/or crypts completely 
(compare Figure 4.11 B to 4.11 A). I performed immunohistochemistry for Dnmt1 and Dnmt3b to 
confirm loss of both proteins in the majority of the epithelium (Figure 4.11 C-F). Many crypts in 
mutants were completely Ki67-negative (Figure 4.11 H), and harbored extensive DNA damage as 
indicated by γH2AX foci (compare Figure 4.11 H versus 4.11 G). TUNEL staining revealed 
increased crypt cell apoptosis in ApcMin/+;Dnmt1;Dnmt3b mutants compared to sibling controls 
(Figure 4.11 J versus 4.11 I). Hyper-proliferative crypts often escaped Cre-mediated Dnmt3b 
deletion (data not shown), consistent with my hypothesis that Dnmt3b is required to preserve 
epithelial integrity in the absence of Dnmt1. 
To assess the overall requirement for Dnmt3b in ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 
survival, I injected tamoxifen into groups of ApcMin/+;Dnmt1loxP/loxP;Dnmt3bloxP/loxP;VillinCreERT2 
mutants and littermate controls at four weeks of age, and weighed mice each day following 
CreERT2 induction. All ApcMin/+;Dnmt1;Dnmt3b mutant mice became severely morbid within three 
weeks following tamoxifen administration and had to be euthanized (Figure 4.11 K). In contrast, 
96% of ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mutant mice survived to three weeks following 
tamoxifen injection (Figure 4.11 K), demonstrating that loss of Dnmt1 alone is non-lethal in the 
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mature intestinal epithelium. I conclude that Dnmt3b is crucial for epithelial survival in the 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mouse model (Figure 4.12 G-I). 
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Discussion 
The results presented above have major implications for the fields of DNA methylation 
and intestinal cancer biology. I show that loss of the DNA methyltransferase Dnmt1 in the ApcMin/+ 
cancer model results in acute hypomethylation and DNA damage (see summary model in Figure 
4.12). I posit that this decreased genomic stability accelerates loss of heterozygosity (LOH) at the 
Apc locus, resulting in increased tumorigenesis and larger tumors (Figure 4.12 F). DNA 
methylation has been linked to genomic instability in multiple contexts, in both cell lines and in 
disease. In the HCT116 colorectal cancer cell line, ablation of catalytically active DNMT1 causes 
cell cycle arrest and apoptosis due to increased chromosomal instability (Chen, Hevi et al. 2007, 
Spada, Haemmer et al. 2007). Global hypomethylation in mice results in chromosome 
duplications and invasive T-cell lymphomas at four months of age (Gaudet, Hodgson et al. 2003), 
and in mouse ES cells, loss of Dnmt1 also causes global hypomethylation and increased 
mutation rates (Chen, Pettersson et al. 1998). In mouse embryonic fibroblasts (MEFs), ablation of 
Dnmt1 causes gradual hypomethylation, deregulated gene expression, and cell death (Jackson-
Grusby, Beard et al. 2001). My work adds to this body of evidence that implicates a crucial role 
for Dnmt1 and DNA methylation in maintaining genome stability. 
Importantly, my study shows increased intestinal adenoma formation after deletion of 
Dnmt1. My experimental paradigm results in intestine-specific, temporal loss of Dnmt1 and acute 
hypomethylation, followed by recovery of global genome DNA methylation, in contrast to prior 
work, which had employed germline hypomorphic Dnmt1 alleles (Laird, Jackson-Grusby et al. 
1995, Cormier and Dove 2000, Eads, Nickel et al. 2002, Trasler, Deng et al. 2003, Yamada, 
Jackson-Grusby et al. 2005). These previous studies thus differed both in the timing of Dnmt1 
deletion and in lack of tissue specificity. Early intestinal development requires Wnt signaling to a 
lesser degree than the established adult stem cell niche (Korinek, Barker et al. 1998, Kim, Mao et 
al. 2007, Mustata, Vasile et al. 2013). In addition, deletion of Dnmt1 during crypt establishment 
has different consequences on global DNA methylation than ablation in mature crypts, and 
causes cell death (Elliott, Sheaffer et al. 2015). Indeed, Laird and colleagues noted that tumor 
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suppression in their model only occurred if hypomethylation was induced early in life (1995). 
Therefore, deletion of Dnmt1 during crypt establishment may lead to decreased cell proliferation 
and a decreased opportunity for tumor initiation. After crypts are established, ablation of Dnmt1 
results in increased proliferation and decreased genome stability, causing accelerated loss of 
ApcMin/+ heterozygosity and adenoma formation (Figure 4.12 D-F). 
Current dogma holds that deletion of Dnmt1 is lethal in all dividing somatic cells (Liao, 
Karnik et al. 2015); however, I find that the rapidly dividing intestinal epithelium can survive 
without Dnmt1. I describe the first in vivo mouse model in which Dnmt3b compensates for loss of 
Dnmt1 in somatic cells. Following Dnmt1 ablation in the adult intestine and acute loss of Dnmt1, 
Dnmt3b activity is induced, and methylation of repetitive elements is restored. However, if 
Dnmt3b is ablated concurrently with Dnmt1, restoration of DNA methylation is prevented, 
resulting in massive DNA damage, and cell death (Figure 4.12 G-I). These results provide 
convincing evidence that Dnmt3b can contribute to maintenance DNA methylation in somatic 
tissues, and strongly suggest that the categories of ‘de novo’ (Dnmt3a and 3b) versus 
‘maintenance’ (Dnmt1) methylation are more plastic than traditionally thought.  
In conclusion, I show that deletion of Dnmt1 in the adult intestinal epithelium of ApcMin/+ 
mice causes accelerated formation of adenomas. Loss of Dnmt1 results in short-term 
hypomethylation, genomic instability, and apoptosis. Dnmt3b is upregulated in response to 
deletion of Dnmt1 in the adult intestine, and is required to recover DNA methylation and epithelial 
integrity. Dnmt1-deficient adenomas maintain global DNA methylation, but continue to display 
increased genomic instability, indicating a fundamental role for Dnmt1 in preserving genomic 
integrity in the intestinal epithelium.  
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Figure 4.1. Analysis of ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mice.  
VillinCreERT2 activity was induced with three daily intraperitoneal injections of 1.6mg tamoxifen 
(TAM) in four-week old ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mutant and ApcMin/+;Dnmt1loxP/loxP 
control mice. To evaluate tumor development, the small intestine and colon were harvested at 
one month and two months following tamoxifen injections, corresponding to two months and three 
months of age, respectively. Acute effects of Dnmt1 ablation were analyzed by harvesting the 
small intestine and colon one week following tamoxifen administration, at five weeks of age. 
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Figure 4.2. Deletion of Dnmt1 in adult ApcMin/+ mice accelerates adenoma initiation.  
ApcMin/+;Dnmt1loxP/loxP mice and ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mice were injected with 
tamoxifen at 4 weeks of age. Intestines were harvested two months or one month following 
tamoxifen treatment, corresponding to three months and two months of age, respectively. 
(A,B) Dnmt1 deletion is maintained two months after tamoxifen treatment in the adult mouse 
small intestinal epithelium. Immunohistochemical staining of Dnmt1 protein is evident in the crypts 
of ApcMin/+;Dnmt1loxP/loxP (A) but absent in ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 (B) mice.  
(C,D) Dramatic increase in tumor formation observed in the three-month old Dnmt1-deficient 
small intestine. Hematoxylin and Eosin staining shows disruption of normal intestinal epithelial 
morphology throughout the entire length of the small intestine in tamoxifen-treated 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mice (D) compared to ApcMin/+;Dnmt1loxP/loxP mice (C). Arrows 
point to adenomas.  
(E) Dnmt1 deletion causes increased incidence of macroscopic tumors in three-month old mice. 
Total number of macroscopic tumors was counted throughout the entire small intestine in 
tamoxifen-treated ApcMin/+;Dnmt1loxP/loxP mice and ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mice at two 
(n≥5) and three (n≥17)  months of age.  
(F) Neoplastic lesions found in Dnmt1-deficient mice are predominantly adenomas. Total number 
of lesions displaying gastrointestinal intraepithelial neoplasia (GIN) and adenoma as determined 
by histopathological scoring were counted in three-month old mice (n=3-8 per group). 
(G) Dnmt1 deletion causes increased size of neoplastic lesions in the small intestine at three 
months of age. Neoplastic lesions were measured in tamoxifen-treated ApcMin/+;Dnmt1loxP/loxP mice 
and Apcmin/+;Dnmt1loxP/loxP;VillinCreERT2 mice at two (n≥24 ) and three (n≥9) months of age.  
(H) Increased number of microadenomas in the two-month old Dnmt1-deficient small intestine. 
Total numbers of microadenomas were counted throughout the entire small intestine in 
tamoxifen-treated ApcMin/+;Dnmt1loxP/loxP mice and ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mice at two 
months of age (n≥5 per group). For all graphs, data are presented as average±SEM; *P<0.05, 
**P<0.01, ***P<0.001 by two-tailed Student’s t-test. Scale bars are 50µm.  
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Figure 4.3. Dnmt1 deletion causes increased incidence of microadenomas in the colon at 
three months.  
(A,B) Dnmt1 deletion was maintained two months after tamoxifen treatment in the adult mouse 
colonic epithelium. Immunohistochemical staining of Dnmt1 protein is evident in the crypts of 
ApcMin/+;Dnmt1loxP/loxP colonic epithelia (A), but is completely absent in 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mutant colon (B).  
(C,D) Increased incidence of neoplastic crypts observed in three-month old Dnmt1-deficient 
colons. β-catenin staining shows an example of a microadenoma (arrow) with nuclear 
accumulation of β-catenin in ApcMin/+;Dnmt1loxP/loxP;Villin-Cre-ERT2 mice (D) compared to 
localization on the cell membrane in the nontransformed colonic epithelia of ApcMin/+;Dnmt1loxP/loxP 
mice (C). Scale bars are 50µm. 
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Figure 4.4. Dnmt1-deficient tumors display increased Wnt signaling.  
The small intestine was collected from three-month and two-month old 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mutants and ApcMin/+;Dnmt1loxP/loxP controls, which were 
tamoxifen-treated at four weeks of age. Immunostaining for several Wnt targets was performed to 
characterize Wnt pathway activation in mutant compared to control tumors. At two months, 
Dnmt1-deficient tumors already exhibit increased Wnt signaling in tumors (B,E,F) relative to 
control tumors at three months (A,D,G). 
(A-C) Immunohistochemical staining reveals increased nuclear β-catenin in three-month old 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mutant (C) compared to ApcMin/+;Dnmt1loxP/loxP control small 
intestine (A). ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mutant tumors at two months of age (B) show 
similar levels of nuclear β-catenin compared to ApcMin/+;Dnmt1loxP/loxP (A) tumors at three months.  
(D-I) Wnt signaling target CycD1 is increased in three-month old Dnmt1-deficient tumors (F) 
relative to control tumors (D). Similarly sized tumors express comparable levels of CycD1 
(compare D to E). CycD1 (red), DAPI (blue). 
(G-I) Three-month old Dnmt1-deficient tumors exhibit increased Sox9 levels (I) compared to 
control tumors (G). Similarly sized tumors display comparable levels of Sox9 (compare G to H). 
Sox9 (red), DAPI (blue). Scale bars are 50µm.  
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Figure 4.5. Loss of Dnmt1 affects genome stability, but not tumor cell proliferation.  
(A) Percentage of cells in mitosis was determined by immunostaining and counting of the 
phospho-H3 positive (pH3+) nuclei in tumors at two months and three months of age. At both time 
points, tamoxifen-treated ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 and ApcMin/+;Dnmt1loxP/loxP displayed 
comparable percentages of pH3+ cells, indicating that loss of Dnmt1 does not affect mitotic rates 
in the small intestine. 
(B-D) Cell proliferation, as visualized by immunohistochemical staining of Ki67, is similar in 
tamoxifen-treated ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 (C,D) compared to ApcMin/+;Dnmt1loxP/loxP 
(B) small intestine.  
(E-G) Neoplastic epithelia contain TUNEL-positive cells at low frequency (yellow arrows) in 
ApcMin/+;Dnmt1loxP/loxP mice (E), which is unchanged in tamoxifen-treated 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mice (F,G). TUNEL (red), E-cadherin (green), DAPI (blue).  
(H-J) The number of neoplastic epithelial cells positive for DNA double-strand breaks, as 
visualized by immunofluorescence staining of γH2AX, is increased in tamoxifen-treated 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mice (I,J) compared to ApcMin/+;Dnmt1loxP/loxP (H) small 
intestines. This is not due to accelerated growth, because similarly sized tumors also show 
increased γH2AX in ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 (I) compared to ApcMin/+;Dnmt1loxP/loxP 
(H). All scale bars: 50µm.  
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Figure 4.6. Dnmt1 deletion in ApcMin/+ mice causes massive epithelial remodeling within 
one week.   
Dnmt1loxP/loxP (A), Dnmt1loxP/loxP;VillinCreERT2 (B), ApcMin/+;Dnmt1loxP/loxP (C), and 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 (D) intestinal epithelium one week after tamoxifen injection. 
Hematoxylin and Eosin staining demonstrates increased severity of the Dnmt1 mutant phenotype 
on the ApcMin/+ background (D) versus control (B).  
(E-H) Immunohistochemistry for Dnmt1 confirms loss of protein in both tamoxifen-treated 
Dnmt1loxP/loxP;VillinCreERT2 (F) and ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mutants (H).  
(I-L) Co-staining for Ki67 (red), a marker of proliferation, and γH2AX (green), which marks DNA 
double-stranded breaks. Both control genotypes (I,K) have minimal γH2AX foci. 
Dnmt1loxP/loxP;VillinCreERT2 mutants have increased proliferation (J), as previously reported 
(Sheaffer, Kim et al. 2014). ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mutants (L) have regions with 
decreased levels of Ki67 and display an increased number of γH2AX foci, reflecting elevated 
genomic instability immediately following Dnmt1 ablation. See also Figure S1. 
(M-P) TUNEL staining to detect apoptosis (red) with E-cadherin (green) to outline the epithelium. 
Controls display no apoptotic nuclei in crypt cells (M,O). Both Dnmt1-mutant genotypes (N,P) 
display increased apoptosis, although there are noticeably more apoptotic nuclei in 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 crypts (P) compared to Dnmt1loxP/loxP;VillinCreERT2 crypts 
(N).  
Scale bars in (A-D) are 100µm. Scale bars in (E-P) are 50µm. 
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Figure 4.7. DNA methylation dynamics after acute Dnmt1 deletion.  
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mice and ApcMin/+;Dnmt1loxP/loxP controls were tamoxifen-
treated at four weeks of age. The intestines were harvested at five weeks (A) or three months (B) 
of age, corresponding to one week and two months post-tamoxifen treatment, respectively. Crypt 
epithelium (A,B) or visible adenomas (B) were isolated by laser capture microdissection. Targeted 
bisulfite sequencing of nine CpGs in the LINE1 repetitive elements was performed to estimate 
global methylation levels.  
 (A) Five-week old ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 intestinal crypts exhibit significantly 
reduced LINE1 methylation levels compared to Dnmt1loxP/loxP;ApcMin/+ control crypts (n=3-4 per 
group). 
(B) No difference in methylation at the LINE elements was detected in normal and tumor cells 
from three-month old ApcMin/+;Dnmt1loxP/loxP and ApcMin/+;Dnmt1loxP/loxP; VillinCreERT2 mice treated 
with tamoxifen at four weeks of age (n=3-11 per group).  
For all graphs, data are presented as average±SEM. ***P<0.001 by two-tailed Student’s t-test.  
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Figure 4.8. Methylation profiling of H19 ICR following Dnmt1 ablation.  
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mice and ApcMin/+;Dnmt1loxP/loxP controls were tamoxifen-
treated at four weeks of age. Intestine was harvested at five weeks (A) or three months (B) of 
age, corresponding to one week and two months post-tamoxifen treatment, respectively. Crypt 
epithelium or visible adenomas were isolated by laser capture microdissection. Targeted bisulfite 
sequencing of six CpGs in the H19 imprinting control region (ICR) was performed to estimate 
maintenance methylation.  
 (A) H19 ICR methylation is preserved in five-week old Dnmt1-mutant ApcMin/+ crypts, similar to 
Dnmt1loxP/loxP;ApcMin/+ control crypts. Average±SEM; (n=3-4).  
(B) No change in H19 ICR methylation is detected in normal and tumor cells from tamoxifen-
treated, three-month old ApcMin/+;Dnmt1loxP/loxP and ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mice.  
Average±SEM; (n=3-11). 
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Figure 4.9. Dnmt1-deficient tumors do not express Dnmt1 protein.  
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 and ApcMin/+;Dnmt1loxP/loxP mice were tamoxifen-treated at 
four weeks of age. Dnmt1 immunohistochemistry was performed in three-month old intestines to 
confirm ablation of Dnmt1 in ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 intestinal tumors (B and B’), 
relative to controls (A and A’). Dnmt1 is expressed in control three-month old adenomas (A, see 
inset in A’), and is not present in age-matched Dnmt1-deficient adenomas (B, see inset B’). Scale 
bars are 50µm. 
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Figure 4.10. Dnmt3b is upregulated one week following Dnmt1 ablation.  
Dnmt3a (A,B) and Dnmt3b (C,D) immunofluorescent staining in 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mutant and ApcMin/+;Dnmt1loxP/loxP control intestinal epithelium 
at one week post-tamoxifen injection. Inset shows 20X image of stained crypt epithelium. Dnmt3a 
levels in mutants (B) are similar to controls (A). Dnmt3b protein levels are increased in mutant 
crypts (D) compared to control crypts (C). Scale bars are 50µm. 
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Figure 4.11. Dnmt3b is required to maintain DNA methylation and epithelial integrity in the 
absence of Dnmt1. 
Loss of Dnmt1 and Dnmt3b in ApcMin/+ mice causes increased apoptosis and is not compatible 
with life.  
(A,B) Hematoxylin and eosin staining reveals increased epithelial disorganization one week after 
tamoxifen injection in ApcMin/+;Dnmt1loxP/loxP;Dnmt3bloxP/loxP;VillinCreERT2 mutants compared to 
ApcMin/+;Dnmt1loxP/loxP;Dnmt3bloxP/loxP controls.  
(C,D) Dnmt1 and (E,F) Dnmt3b protein staining confirms ablation of respective proteins in the 
intestinal epithelium of five-week old ApcMin/+;Dnmt1loxP/loxP;Dnmt3bloxP/loxP;VillinCreERT2 mutants.  
(G,H) Co-staining for Ki67 (red), a marker of proliferation, and γH2AX (green), which marks DNA 
double-strand breaks. ApcMin/+;Dnmt1;Dnmt3b;VillinCreERT2  mutants (H) have decreased Ki67 
staining and increased γH2AX foci compared to controls (G).  
(I,J) Costaining of TUNEL (red), to mark apoptotic nuclei, and Epcam (green) to outline the 
epithelium. ApcMin/+;Dnmt1;Dnmt3b;VillinCreERT2  mutants (J) have increased apoptosis 
compared to controls (I). Scale bars are 50µm. 
(K) Dnmt1; Dnmt3b deficient ApcMin/+ mice are not viable. Percent survival of mice of the indicated 
genotypes following tamoxifen injection (TAM) at four weeks of age. *P<0.05, ***P<0.00001, by 
log rank test (n≥7 per group). 
  
	   	    133	  
  
	   	    134	  
Figure 4.12. Functional analyses of DNA methylation in ApcMin/+ cancer development. 
Mice and intestinal epithelium in (A-D,F,G) are shown in black, representing normal DNA 
methylation levels. The intestinal epithelium in (E,H) is white, indicating acute hypomethylation.  
(A-C) ApcMin/+;Dnmt1loxP/loxP control mice maintain DNA methylation in all tissues, including the 
intestinal epithelium. At five weeks, mice display normal DNA methylation levels, and no tumor 
formation (B). At three months of age, ApcMin/+;Dnmt1loxP/loxP intestine has preserved DNA 
methylation, and harbors multiple adenomas (C, adenomas are outlined in green). 
(D-F) In the current study, intestine-specific ablation of Dnmt1 was induced in four-week old 
ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 mice (D). Mice displayed acute global hypomethylation and 
increased genome instability in the intestine at five weeks of age (E, red circles indicate DNA 
damage). At three months of age, mice had recovered global DNA methylation, but exhibited 
significantly more tumors compared to controls (F, large adenomas outlined in green). These 
tumors also displayed increased genomic instability (F), distinct from control tumors at the same 
time point (C).  
(G-I) Loss of both Dnmt3b and Dnmt1 in the adult intestinal epithelium was induced using 
ApcMin/+;Dnmt1loxP/loxP;Dnmt3bloxP/loxP;VillinCreERT2 mice (G). Five-week old mice displayed 
severe hypomethylation and genome instability (H). Mice failed to recover and died within 21 
days of Dnmt1/Dnmt3b ablation (I). 
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Chapter 5 
Conclusions and Future Directions 
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Summary and Conclusions 
I have shown that Dnmt1 is an essential regulator of genomic stability in the murine 
intestinal epithelium. Loss of Dnmt1 in the neonatal intestine causes hypomethylation, irreparable 
DNA damage, and apoptosis of progenitor cells. As a result, these mice do not compete well for 
maternal resources, and die before weaning. Dnmt1 ablation in the adult intestinal epithelium also 
results in acute DNA hypomethylation and DNA damage. However, the adult ApcMin/+ intestine 
compensates for these aberrations by increased Dnmt3b activity, and recovers normal DNA 
methylation levels within two months of Dnmt1 ablation. These results have implications for 
several fields of research, which I outline below. 
 
Neonatal intestinal progenitors and adult intestinal stem cells are distinct cell populations, 
with differing requirements for Dnmt1 
I have demonstrated that Dnmt1 is required to varying degrees in the intestinal 
epithelium, dependent on the stage of intestinal maturity. Dnmt1 is required to maintain progenitor 
cells in the neonatal intestinal epithelium, and loss of Dnmt1 during intestinal development results 
in perinatal lethality. Dnmt1 ablation in the adult intestinal epithelium also results in acute DNA 
hypomethylation and DNA damage, but is not essential for intestinal epithelial survival, as 
reported previously (Sheaffer, Kim et al. 2014). Interestingly, the adult intestine recovers DNA 
methylation following the immediate effects of Dnmt1 deletion, indicating a distinct difference in 
the requirement of Dnmt1 in the developing, in comparison to mature, intestinal epithelium. The 
distinct adult and perinatal Dnmt1-mutant phenotypes are not an artifact of differential Cre 
transgene activity, because tamoxifen-treated Dnmt1loxP/loxP;VillinCreERT2 neonatal mice also 
exhibit decreased viability (data not shown). Therefore, these data indicate important differences 
in proliferative processes in the developing versus adult intestinal epithelium. 
It is important to consider that the murine neonatal intestine is comparable to ~10 week-
old human fetal intestine (Montgomery, Mulberg et al. 1999). Thus, the mouse intestine at birth is 
not fully mature, and the intestinal stem cell niche is not equivalent to the crypts found in adult 
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intestinal epithelium. Indeed, I discovered that the rate of proliferation in the perinatal intestine is 
dramatically increased compared to adult intestinal epithelium, similar to that reported by other 
groups (Figure 3.13; (Itzkovitz, Blat et al. 2012)). Wnt signaling, which is required to maintain 
proliferation in adult intestinal epithelial crypts, is not necessary in the developing intestine until 
after nascent villus formation at E15.5 (Korinek, Barker et al. 1998). Recent studies of intestinal 
organoid cultures derived from late-gestation and neonatal mouse intestine have further 
supported the notion that intervillus progenitors in the neonate are distinct from the crypt-based-
columnar stem cell population in the adult (Fordham, Yui et al. 2013, Mustata, Vasile et al. 2013). 
In vitro, mature crypts form organoids with budding outgrowths that are anomalous to intestinal 
crypts in vivo. Although progenitors from embryonic and neonatal intestinal epithelium also form 
budding organoids in vitro, nearly half of late gestation intestinal progenitors form spheroids 
(Fordham, Yui et al. 2013, Mustata, Vasile et al. 2013). Spheroids are small cysts of proliferative 
intestinal cells, which do not produce buds during prolonged culture. Expression of Wnt signaling 
factors correlates with progenitor maturation and budding-organoid formation: in contrast to 
organoids derived from adult crypts, progenitors isolated from embryonic stages prior to E18.5 
express low levels of Wnt, and form spheroids in culture (Fordham, Yui et al. 2013). Differing 
requirements for Wnt signaling during development indicate distinct regulation of proliferation and 
progenitor cell expression programs.  
The differential requirement for Dnmt1 and DNA methylation during development relative 
to fully mature organs may be a global event not limited to the intestinal epithelium. In the 
developing pancreas, Dnmt1 is required to prevent p53-dependent apoptosis (Georgia et al), 
whereas in the mature pancreas, Dnmt1-mediated methylation is required to maintain endocrine 
β-cell identity (Dhawan et al Dev Cell 2011). It will be interesting to determine the requirements 
for Dnmt1 in other organs, both during development and in the adult organ, which will help 
elucidate the mechanisms underlying tissue-specific epigenetic regulation. 
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Dnmt1 and DNA methylation are essential for genomic stability in the intestinal epithelium 
My results indicate that loss of Dnmt1 in the perinatal, adult, and cancer-prone ApcMin/+ 
intestinal epithelia causes an increase in double strand breaks, demonstrating that Dnmt1 is 
essential for maintaining genome integrity in the small intestine. Deletion of Dnmt1 induces 
hypomethylation and genomic instability in various cell types in vitro, including mouse ES cells, 
mouse embryonic fibroblasts, and human HCT116 colorectal cancer cell lines. Dnmt1 
hypomorphic mice exhibit increased chromosomal duplications and rearrangements, and develop 
invasive T-cell lymphomas at approximately four months of age. It is important to note that these 
effects are not restricted to DNMT1 deficiency. Loss of Dnmt3b also induces hypomethylation and 
chromosomal instability in mouse embryonic fibroblasts (Dodge, Okano et al. 2005), suggesting 
that both Dnmt1 and Dnmt3b are crucial for maintaining DNA methylation and preserving genome 
integrity. Mutations in DNMT3B underlie Immunodeficiency, Centromeric region instability, and 
Facial anomalies (ICF) syndrome and cause hypomethylation at centromere-adjacent 
heterochromatin, leading to chromosomal translocations and deletions (Hansen, Wijmenga et al. 
1999, Xu, Bestor et al. 1999). My studies corroborate these findings, further establishing that 
DNA methylation is crucial to maintaining genomic stability.  
 Chromosomal instability also correlates with DNA hypomethylation in sporadic human 
colorectal cancer (CRC) (Lengauer, Kinzler et al. 1997, Rodriguez, Frigola et al. 2006). Although 
hypomethylation occurs early in human CRC development (Feinberg and Vogelstein 1983, 
Gama-Sosa, Slagel et al. 1983, Goelz, Vogelstein et al. 1985, Feinberg, Gehrke et al. 1988), it is 
largely unknown to what extent loss of DNA methylation contributes to tumor progression. The 
majority of DNA methylation CRC research has focused on the hypermethylation of tumor 
suppressor gene promoters, which is known to cause decreased expression of genes important 
for mismatch repair and cell cycle control (Esteller 2005). These early studies suggested that 
tumor suppressor gene hypermethylation is a key step in tumor progression, in both human CRC 
and relevant mouse models (Esteller, Corn et al. 2001, Eads, Nickel et al. 2002).  
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The ApcMin/+ mouse recapitulates the human familial adenomatous polyposis (FAP) 
syndrome (Moser, Pitot et al. 1990, Su, Kinzler et al. 1992), and is commonly utilized as an in 
vivo model for human CRC. FAP patients and ApcMin/+ mice have only one functional copy of the 
Apc gene. Apc is a critical component of the cytoplasmic β-catenin destruction complex, and loss 
of Apc allows increased nuclear β-catenin localization, Wnt pathway stimulation, and uncontrolled 
cell proliferation (Pinto, Gregorieff et al. 2003, Sansom, Reed et al. 2004). Thus, loss of 
heterozygosity (LOH) at the Apc locus triggers tumor development (Su, Kinzler et al. 1992, 
Luongo, Moser et al. 1994). ApcMin/+ mice develop multiple tumors in the small intestine by three 
months of age (Moser, Pitot et al. 1990, Su, Kinzler et al. 1992), and have served as an efficient 
model for in vivo studies of intestinal tumor development and progression.  
Several studies have employed global hypomorphic Dnmt1 alleles in ApcMin/+ mice, and 
report that Dnmt1 is required for tumor progression in the ApcMin/+ model (Laird, Jackson-Grusby 
et al. 1995, Cormier and Dove 2000, Eads, Nickel et al. 2002, Trasler, Deng et al. 2003, Yamada, 
Jackson-Grusby et al. 2005). These reports are ultimately inconclusive due to possible intestine-
independent or developmental effects of decreased Dnmt1 expression. Indeed, my own work 
demonstrates that Dnmt1 is essential for maintenance of perinatal intestinal progenitor cells. Our 
lab also found that global loss of the mesenchymal transcription factor Foxl1 increases intestinal 
tumor load in ApcMin/+ mice (Perreault, Sackett et al. 2005), demonstrating that ApcMin/+ tumor 
multiplicity is influenced by factors not expressed in the intestinal epithelium. The reduced 
tumorigenesis phenotypes previously described in Dnmt1-hypomorphic ApcMin/+ mice are likely 
due to decreased proliferation of progenitor cells in the neonatal intestine, which would provide 
fewer opportunities for tumor initiation. Alternatively, increased genomic instability in these mice 
from early development onward may actually prohibit tumor progression via increased levels of 
apoptosis in damaged cell populations (Halazonetis, Gorgoulis et al. 2008). In the adult intestinal 
epithelium, inducible deletion of Dnmt1 causes acute hypomethylation of intestinal stem cell 
genes and two-fold expansion of the proliferative crypt zone (Sheaffer, Kim et al. 2014), which 
suggests that hypomethylation promotes proliferative processes in the intestinal epithelium. 
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Intestinal tumor progression could be due in part to the incomplete differentiation caused by 
hypomethylation, and ablation of Dnmt1 may exacerbate this process.  
To directly determine the function of epithelial Dnmt1 in intestinal tumorigenesis, I 
employed an intestine-specific, inducible ablation model to delete Dnmt1 in ApcMin/+ mice. In stark 
contrast to the previously published studies, I observed increased tumorigenesis two months 
following intestinal epithelial-specific ablation of Dnmt1 in four-week old ApcMin/+ mice. As 
predicted by my preceding work, Dnmt1-ablated tumors displayed multiple γH2AX foci, a marker 
of DNA double-strand breaks and genomic instability. I also noted increased microadenoma 
formation, indicating an accelerated rate of tumor initiation, although the proliferation rate of 
neoplastic cells was not altered relative to controls. To determine the underlying mechanism of 
this increased tumor load, I analyzed mice one week following Dnmt1 deletion, and observed 
global hypomethylation and increased levels of DNA damage and crypt cell apoptosis relative to 
controls. ApcMin/+ mice have weakened responses to stressors, such as irradiation (Tao, Tang et 
al. 2015), and I show that loss of Dnmt1 in ApcMin/+ mice precipitates massive epithelial damage 
and remodeling. Previously, Yamada and colleagues reported that Dnmt1-hypomorphic ApcMin/+ 
mice displayed an increased number of microadenomas (2005). They concluded that loss of 
Dnmt1 augmented LOH at the Apc locus, but did not provide a satisfying mechanism to explain 
this phenotype. I propose that the genomic instability induced following loss of Dnmt1 increases 
LOH, resulting in accelerated tumorigenesis and ultimately larger tumors.  
My results indicate that hypomethylation is a strong instigator of tumor development, as 
hypomethylation causes genomic instability, driving accelerated LOH at the Apc locus and 
increased tumorigenesis. As global hypomethylation correlates with chromosomal instability in 
CRC (Lengauer, Kinzler et al. 1997, Rodriguez, Frigola et al. 2006), and loss of Dnmt1 leads to 
increased chromosomal translocations and instability in several contexts (discussed above), it is 
possible that early genomic hypomethylation induces genomic instability. Thus, loss of Dnmt1 
could contribute to the accumulation of multiple mutations during development from adenoma to 
carcinoma. Future work will determine the precise function of DNA hypomethylation in early tumor 
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formation, using both in vivo mouse models and patient-derived in vitro organoids. The CRISPR-
Cas9 genome editing technology has been optimized for human intestinal organoid culture, and 
was utilized to mutate genes with putative roles in CRC development (Matano, Date et al. 2015). 
Mutated organoids were engrafted under the kidney capsule in immune-deficient mice to test 
tumor formation in vivo (Matano, Date et al. 2015). These models can be utilized and combined 
with next-generation sequencing technologies to precisely assess how hypomethylation 
contributes to genomic instability at different stages of CRC, and if genomic hypomethylation in 
mouse models has the same effect as in human CRC. 
 
Dnmt3b can compensate for Dnmt1 in the intestinal epithelium in vivo 
Strikingly, by two months post-Dnmt1 ablation, DNA methylation levels at repetitive 
elements in Dnmt1-deficient ApcMin/+ tumors and adjacent epithelia were comparable to controls. 
These results were also confirmed by immunofluorescent staining with a 5-methylcytosine 
antibody (data not shown). I hypothesized that the de novo methyltransferases (Dnmt3a and 
Dnmt3b) become activated following Dnmt1 deletion, and are necessary for remethylation of the 
genome and phenotypic recovery. Indeed, I observed increased Dnmt3b protein levels in Dnmt1-
deficient ApcMin/+ intestinal crypts, relative to ApcMin/+ controls. Accordingly, I tested the 
requirement for Dnmt3b in the survival of ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 tamoxifen-treated 
mice. Strikingly, when I deleted Dnmt1 and Dnmt3b concurrently in the ApcMin/+ intestinal 
epithelium, these mice were unable to recover, and died within three weeks of tamoxifen 
administration. Compared to Dnmt1-mutant ApcMin/+ mice, Dnmt1;Dnmt3b-deficient ApcMin/+ mice 
displayed extensive DNA damage and high levels of crypt cell apoptosis. These results clearly 
demonstrate that Dnmt3b is required to recover and maintain DNA methylation in the intestinal 
epithelium of Dnmt1-deficient ApcMin/+ mice. Importantly, my data directly contradict the current 
DNA methylation dogma, and provide a novel in vivo model for Dnmt1 compensation by a de 
novo methyltransferase.  
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In the field of DNA methylation, it is standard to refer to Dnmt1 as the ‘maintenance’ 
methyltransferase, whereas Dnmt3a and Dnmt3b are termed the ‘de novo’ methyltransferases. 
My data strongly suggest that these definitions need to be revised to better reflect the current 
body of literature. It has been suggested that all replicating somatic cells require Dnmt1 for cell 
survival (Liao, Karnik et al. 2015). I demonstrate that this is not the case in the mature intestinal 
epithelium, one of the most highly self-renewing tissues in mammals. My work corroborates in 
vitro evidence showing that loss of Dnmt1 does not lead to complete hypomethylation (Li, Bestor 
et al. 1992). In some cases, de novo methyltransferases are essential for methylation of certain 
elements or enhancers, and cannot be compensated for by Dnmt1. For example, hematopoietic 
stem cells (HSCs) require Dnmt3a for normal self-renewal and differentiation processes (Challen, 
Sun et al. 2012). Loss of Dnmt3a in HSCs causes demethylation at essential stem cell genes, 
inducing hyper-proliferation and reducing differentiation rates (Challen, Sun et al. 2012). Dnmt3b 
also contributes to silencing of germline genes in somatic cells (Velasco, Hubé et al. 2010), and 
maintenance methylation in ES cells (Liang, Chan et al. 2002, Chen, Ueda et al. 2003). My 
results provide additional evidence that the de novo methyltransferase Dntm3b can perform 
maintenance methylation in vivo. 
In the future, to determine by which molecular mechanism Dnmt3b is functioning as a 
‘maintenance’ methyltransferase, I could take advantage of the mouse models described in 
Chapter 4, in which Dnmt1 is inducibly ablated in the adult ApcMin/+ intestinal epithelium. In these 
experiments, ApcMin/+;Dnmt1loxP/loxP;VillinCreERT2 (mutant) and ApcMin/+;Dnmt1loxP/loxP (control) 
mice are tamoxifen-treated at four weeks of age to induce Dnmt1 deletion, and intestinal crypts 
are harvested one week and two months following tamoxifen injection. These time points enable 
observation of acute DNA hypomethylation immediately following Dnmt1 ablation compared to 
the long-term recovery of DNA methylation, which requires Dnmt3b. Whole-genome bisulfite 
sequencing from control and mutant intestinal crypts at these two time points following Dnmt1 
deletion would reveal how methylation patterns are decreased and subsequently recovered over 
time. ChIP-Seq for Dnmt1 and Dnmt3b from these cohorts of mice would allow me to characterize 
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compensation by Dnm3b in mutant crypts. At one week following Dnmt1 ablation, I would predict 
to see loss of Dnmt1 localization in mutant crypts, and normal Dnmt3b distribution, relative to 
respective ChIP-Seq of control crypts. Following recovery of DNA methylation at two months post 
Dnmt1 deletion, I would expect Dnmt3b ChIP-Seq profiles from mutants to mimic Dnmt1 ChIP-
Seq profiles in control crypts. To elucidate the mechanism underlying Dnmt3b maintenance 
methylation, I could perform immunoprecipitation of Dnmt3b, followed by mass spectrometry to 
identify the protein complexes associated with Dnmt3b in mutant crypts, compared to controls. 
Mutant crypts may exhibit differential Dnmt3b binding at two months post-Dnmt1 ablation, 
compared to control crypts and mutant crypts at one week following tamoxifen treatment. These 
experiments would define how DNA methylation and Dnmt binding profiles change during the 
course of DNA methylation loss and recovery, and provide an exciting model to analyze drastic 
chromatin alterations in vivo.  
 
Future Directions: An Epigenetic Map of Intestinal Differentiation 
My research has significance in multiple fields. In intestinal biology, my work strongly 
suggests distinct differences between developing and mature crypts. Understanding crypt 
development is essential for developing new cancer therapeutics targeting aberrant stem cell 
activity. Since the Lgr5+, CBC stem cell population is touted as being the cell of origin in 
colorectal cancers (Barker, Ridgway et al. 2009, Merlos-Suárez, Barriga et al. 2011, Barker, van 
Oudenaarden et al. 2012), understanding how these cells develop within the context of the 
intestinal crypt is crucial to advancing intestinal disease research. Recent studies employing the 
organoid mini-gut model system has also shown that embryonic and fetal intestinal progenitors 
have distinct expression profiles, and form unique cyst-structures in culture (Fordham, Yui et al. 
2013, Mustata, Vasile et al. 2013). Use of organoid model systems to enrich for homogenous 
populations of specific cell types will be useful in studying progenitors during intestinal 
development, as well as epigenetic changes that occur during mature intestinal differentiation. 
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 The intestinal epithelium is a remarkable system due to the high rate of cell turnover and 
diversity of cell types within the compact crypt-villus architecture. Indeed, the crypt-villus subunit 
is an ideal in vivo model of adult intestinal stem cell proliferation, renewal, and differentiation. 
However, to fully understand how epigenetic marks interact and influence this process, we must 
isolate and characterize multiple marks and transcription factor binding profiles of stem, 
progenitor, and differentiated cell populations. In the past decade, many markers for specific cell 
types in the intestinal epithelium have been defined, the vast majority of which label stem cells, 
such as the Lgr5+ crypt-based-columnar stem cells (CBC) (Barker, van Es et al. 2007). 
Fluorescent-activated cell sorting (FACS) isolation of CBCs is feasible by utilization of knock-in 
mice, which express fluorescent proteins downstream of stem cell gene promoters (Barker, van 
Es et al. 2007). This has enabled transcriptome sequencing, whole-genome bisulfite sequencing, 
and ChIP-Seq analysis of the CBC stem cell population (Merlos-Suárez, Barriga et al. 2011, 
Kaaij, van de Wetering et al. 2013, Kim, Li et al. 2014, Sheaffer, Kim et al. 2014). Progenitor cell 
populations can also be isolated using genetic mouse models. For instance, Notch-deficient mice 
display increased secretory progenitors in crypts; these crypt cells can be isolated using EDTA 
dissociation methods (Kim, Li et al. 2014). Differentiated cells can be selected for using similar 
genetic methods, such as loss of Atoh1 to enrich for enterocytes in villi (Kim, Li et al. 2014). 
These methods have been utilized in several reports that describe differences in 
epigenetic marks and transcription factor binding between CBC, progenitor, and differentiated 
cells (Verzi, Shin et al. 2013, Kim, Li et al. 2014, Sheaffer, Kim et al. 2014). These studies have 
indicated a major role for transcription factors, such as Cdx2, in maintenance of chromatin 
profiles during intestinal differentiation (Verzi, Shin et al. 2013, Kim, Li et al. 2014), and a function 
for DNA methylation in restricting the proliferative cell region (Sheaffer, Kim et al. 2014). 
Interestingly, all of these reports found that the most dynamic regions of epigenetic control are 
associated with enhancer marks, including H3K27ac and H3K4me2. Although many epigenetic 
marks have been profiled in intestinal cells, a broad study profiling multiple repressive 
(H3K27me3, H3K9me3) and activating marks (H3K4me3, H3K79me2, H3K36me3) in all of the 
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intestinal cell sub-populations has not yet been published. A complete and detailed epigenomic 
map of intestinal differentiation will be an invaluable tool in the study of intestinal development, 
homeostasis, and disease. 
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